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ABSTRACT
   The objective of this study was to assess hypertension care in eastern and southwestern
Finland during 1982-1997, in the Helsinki-Vantaa region during 1992-1997 and in the Oulu
region in 1997. The data were derived from four independent cross-sectional national
FINRISK population surveys conducted in 1982, 1987, 1992 and 1997. For each survey,
a random sample of the population aged 25-64 years were chosen from the national
population register. Altogether 29036 men and women participated in these surveys. The
efficacy of non-pharmacological treatment of hypertension in primary care setting was
assessed in a two-year randomised controlled trial conducted in nine health care centres in
eastern Finland with 715 hypertensive men and women aged 25-74 years. The intervention
was based mainly on intensified lifestyle counselling provided by public health nurses.
   During 1982-1997, the mean systolic blood pressure (BP) and the prevalence of
hypertension decreased significantly in both genders and in all areas except in men in
Helsinki-Vantaa region during 1992-1997. The mean diastolic BP decreased significantly
only in men and women in eastern Finland. The rates for awareness, drug treatment and
control of hypertension improved significantly in all areas except in men in Helsinki-Vantaa
region. Mean total cholesterol decreased significantly in both normotensive and hypertensive
populations. Mean high density lipoprotein cholesterol increased in all subjects except in men
unaware of their hypertension, and the mean value remained significantly higher in the drug-
treated hypertensive subjects compared to the rest of the population. The prevalence of
smoking decreased significantly in normotensive and in drug-treated hypertensive men, but
increased significantly in drug-treated hypertensive women. The mean body mass index and
alcohol consumption increased in the whole population, but especially in the hypertensive
subjects. The proportion of subjects engaging in recommended levels of self-reported leisure-
time physical activity increased significantly in all BP groups, except in women unaware of
their hypertension. In the separate trial of non-pharmacological treatment of hypertension in
primary health care, the net reductions in systolic and diastolic BP at two years were
significantly greater in the intervention group compared to subjects assigned to usual care
among the participants with no antihypertensive drug treatment, but not among the drug-
treated subjects.
   In conclusion, hypertension care has improved significantly in Finland during 1982-1997.
In the future, the observed trends in mean body mass index and in alcohol consumption of the
whole population should be reversed to maintain these trends. The health behaviour of newly
detected hypertensive individuals should be monitored and intervened in primary health care
in a more systematic and efficient way than currently. In addition, effective antihypertensive
drug treatment should be initiated in persons with moderate or high cardiovascular risk early
enough if lifestyle modification does not give satisfactory results.
National Library of Medicine Classification: WG 340
Medical Subjects Headings: hypertension; Finland; randomised controlled trial; cross-
sectional studies; obesity; hypercholesterolaemia; life change events
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ACE Angiotensin-converting enzyme
BMI Body mass index
BP Blood pressure
CHD Coronary heart disease
CI Confidence interval
CVD Cardiovascular disease
DBP Diastolic blood pressure
HDL High density lipoprotein
LDL Low density lipoprotein
LIFE Losartan Intervention For Endpoint reduction
LIHEF Lifestyle Intervention against Hypertension in Eastern Finland
LVH Left ventricular hypertophy
MONICA Monitoring of Trends and Determinants in Cardiovascular Disease
MRFIT Multiple Risk Factor Intervention Trial
SBP Systolic blood pressure
VO2max Maximal oxygen uptake
WHO World Health Organization
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1   INTRODUCTION
   Many long-term epidemiological studies have shown that elevated blood pressure (BP) is an
independent and strong predictor for cardiovascular diseases (CVD) (1, 2). This evidence is
further supported by numerous antihypertensive drug trials, which have demonstrated the
favourable effect of BP reduction on the incidence of these diseases (3).
   In Finnish men the mortality rate from coronary heart disease (CHD) was the highest in the
world in the 60’s (4). Thereafter, the age-adjusted death rate from CHD in men aged 35-64
years has decreased by 65 % (5). Also the rates for stroke mortality in both sexes and for
CHD mortality in women have greatly declined. More than half of this reduction is estimated
to have occurred due to reductions in the levels of the three major cardiovascular risk factors:
smoking, serum cholesterol and BP (6, 7). Despite the favourable development detected in
community control of hypertension in Finland since the beginning of the 70’s (8), the BP
levels in Finland were still among the highest in the world in the mid-80’s (9). Finland took
part of the multinational MONICA (Monitoring of Trends and Determinants in
Cardiovascular Disease) project which  was initiated by the World Health Organization
(WHO) in 1982 (10). This international collaboration with highly standardized field survey
methods enabled the follow-up of the community control of hypertension in Finland that
originally started in 1972 when the North Karelia Project was launched (11).
   Evidence from prospective observational studies has established that the risk for CVD in
hypertensive subjects depends highly on coexistence of other cardiovascular risk factors
(12-14). This fact has also been taken into account in the latest national and international
hypertension guidelines which emphasize the subject's absolute risk estimated from the levels
of the main CVD risk factors as the key for treatment decisions (15-17). Despite the
importance of the topic, there are virtually no data available of the trends in other
cardiovascular risk factors of the hypertensive subjects at the population level, although some
cross-sectional data exists (18, 19). The WHO MONICA project provided an opportunity to
investigate also this issue.
   From the public health point of view, the main determinants for the changes in BP levels are
the changes in lifestyle factors affecting BP. The efficacy of lifestyle modification in
prevention and treatment of high BP has been shown in many randomised, clinical trials
(20-22). These trials with rather intensive intervention have been mainly performed in
16
academic study centres with expert personnel trained for the trial. So far, the intervention
methods used in these trials have not been tested in a larger-scale controlled clinical trial in
every-day clinical practice. Therefore, a 2-year open randomised, controlled trial of Lifestyle
Intervention against Hypertension in Eastern Finland (LIHEF) was conducted during 1996-
1999 to assess the feasibility and efficacy of moderately low intensity patient-counselling
programme planned for hypertensive subjects in primary health care.
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2  REVIEW OF THE LITERATURE
2.1 Physiology and measurement of blood pressure
   The circulatory system consists of the heart and blood vessels. Blood is ejected from the left
ventricle of the heart to the aortic arch during systole. Thereby the blood is transported
through smaller arteries and arterioles to capillaries which are responsible for the exchange of
nutrients, electrolytes, hormones and other active substances between the blood and tissue
interstitial fluid. The veins transport blood back to the heart. BP means the force exerted by
the blood against the vessel wall (23). Systolic BP (SBP) is defined as the peak BP measured
during the heart systole and diastolic BP (DBP) as the lowest BP measured during heart
diastole, respectively. The subject’s BP level is determined from the equation: BP = cardiac
output x peripheral resistance. Hypertension is preceded by the increase in either or both of
the components in the equation. SBP is dependent of the stroke volume of the left ventricle, of
elasticity of the aorta and other large arteries, and of the peripheral resistance which is
determined by the diameter of the arterioles. DBP is determined mainly by the peripheral
resistance and also to some extent by the elasticity of the large arteries. In western countries,
the average SBP level increases progressively along with the increasing age due to the
stiffening of the arteries. Conversely, the age-related increase in DBP levels off at around the
age of 50 years and tends to decline thereafter (24). However, in some acculturated
populations the BP level does not increase along with age (25).
   A subject’s BP level is conventionally measured indirectly by devices using an inflatable
cuff to occlude the artery of an extremity - usually the right brachial artery (26). SBP and
DBP values are determined either oscillometrically or by detection of pulse sounds. The
classical mercury sphygmomanometer, introduced by Riva-Rocci already in 1896 and
modified by Korotkoff in 1905 using the auscultatory method, is the most commonly used
apparatus for BP measurement (27). It is still kept as the reference in comparisons with the
other BP measurement devices, since it carries the main epidemiological evidence of the long-
term risks associated with the elevated BP. With this technique, SBP is determined as the
pressure where the occluded artery opens and pulse sounds are heard at each heart beat (phase
I of the Korotkoff sounds). Respectively, DBP is usually determined as the point where all the
pulse sounds completely disappear (phase V of the Korotkoff sounds).
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   The accuracy of BP measurement using this method is vulnerable to many sources of error,
of which the observer error is the most important  one. However, this type of error can be
diminished by careful and standardized observer training, which is of major importance in the
follow-up of hypertensive patients and especially in hypertension research (28).
2.2 Definition of hypertension
   The relationship between BP and adverse health effects is graded but continuous, with no
actual threshold value below which there would not be any reduction in risk for the diseases
associated with the increase in BP (1). Therefore, in theory, the classification of subjects into
categories of ”normotensive” and ”hypertensive” is to some extent artificial. It has been
suggested that the best operational definition for hypertension would be the level at which the
benefits associated with reduction of BP would exceed the possible disadvantages of
treatment (29). However, to be able to identify high-risk individuals and to provide guidelines
for management of high BP, classification of BP is mandatory (30).
   Due to the increasing knowledge from the benefits of BP lowering derived from the drug
trials, the definition of high BP has undergone many changes towards lower and lower
threshold values during the last 40 years. Usually this threshold has been set to the level
where the long-term risk for CVD events is doubled (31). Although there has been quite
marked variation in classification of BP between the hypertension guidelines proposed by
different institutions during these years, the latest of the most recognized guidelines are quite
uniform with this respect (15-17). The classification of BP levels by the latest Finnish
Hypertension Society guidelines are presented in Table 1.
   In addition to the observer's performance, the accuracy of BP measurement can be affected
by several other factors (32-34). An individual's BP tends to vary markedly even in highly
standardized conditions. Therefore the clinical diagnosis of hypertension should be based on
multiple BP measurements, taken on several separate occasions. In the current Finnish
Hypertension guidelines the diagnosis and classification of hypertension is recommended to
be based on a mean value of BP measurements taken on at least four separate consecutive
occasions with two measurements at each visit, and with the patient in a sitting position (35).
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Table 1. Classification of systolic and diastolic blood pressure levels according to the Finnish
Hypertension Society Guidelines. Modified from (35).
Category SBP, mmHg DBP, mmHg
Optimal < 120 and < 80
Normal < 130 and < 85
Satisfactory 130-139 and 85-89
Hypertension
     Mild 140-159 or 90-99
     Moderate 160-179 or 100-109
     Severe > 180 or > 110
2.3 Aetiology of hypertension
2.3.1 Overview
   Roughly 90-95 % of hypertensive subjects have no definite reason for their elevated BP, i.e.
they have primary or, in other words, essential hypertension. In the rest of the cases, some
specific disease or condition causing BP elevation is present (36, 37). The most common
reasons for the secondary hypertension are renal parenchymal diseases, obliterative renal
artery disease, primary aldosteronism and oral contraceptive use (31). From the public health
point of view, of these two main forms of hypertension, primary hypertension is of much
more importance and is therefore the main topic of this review.
   Although the exact origin of the primary hypertension is still unknown, many hypotheses
exist (Figure 1). It has been argued that renal dysfunction, too subtle to be detected and
leading to increased retention of salt and water by many different mechanisms, may be the
leading cause for primary hypertension (38, 39). It has also been suggested that some defects
in cell ion transport could increase the movement of sodium into the cell and thereby to the
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increase in intracellular calcium concentration and in vascular tone (40). The other main
hypotheses include vascular hypertrophy caused by multiple vasoactive substances,
sympathetic nervous hyperactivity, hyperinsulinemia and endothelial cell dysfunction (41-44).
   From a population perspective, it can be concluded that the primary hypertension develops
from the complex interaction between the inherited genes and the environmental factors. It
has been estimated that 30-40 % of BP variation is determined by genetic factors and the rest
by the environment. It has been proposed that the mean value of BP in the population is
determined by environmental factors, whereas the subject's BP rank or range of possible
variation is determined by genes (45).
Figure 1. Some of the factors involved in the pathogenesis of hypertension. Reprinted with
permission of Williams & Wilkins from (46) .
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2.3.2  Genetic factors
   Numerous studies in various parts of the world show that the levels of both SBP and DBP
correlate significantly within families (47, 48). So far, no definite causally related genetic
marker for primary hypertension has been established, although some polymorphisms have
been found to be associated with hypertension in some populations (49, 50). Genetically,
primary hypertension is currently believed to be of polygenic origin, although some rare
monogenic forms of hypertension have been established (51-53). These genes will hopefully
work as a tool for better understanding of the pathophysiology of primary hypertension and
simultaneously lead to possible new proceedings in antihypertensive drug therapy (54).
Hopefully, in the future along with possible progress in the genetic epidemiology of
hypertension we will be able to distinguish susceptible subjects who would benefit most from
environmental manipulation already during childhood (55).
2.3.3  Environmental factors - the evidence from the observational studies and clinical
trials
2.3.3.1  Body weight
Epidemiological studies
   The positive, independent association between either overweight (body mass index, BMI
above 25 kg/m2) or obesity (BMI above 30 kg/m2) and elevated BP has been verified in
numerous cross-sectional population-based studies. Depending of the magnitude of
overweight, the prevalence of hypertension has been documented as 1.5-6 times higher in
overweight or obese subjects compared to subjects with normal weight (56, 57). In the
international INTERSALT study of 52 populations worldwide, a 10 kg increase in body
weight was associated with a 3.0 mmHg increase in SBP and a 2.2 mmHg increase in DBP,
respectively (58). In prospective epidemiological studies, obesity and weight gain have been
associated with the increased risk of hypertension (59). This risk has been shown to be
especially high in subjects with abdominal adiposity (60-62). Also the risk for
antihypertensive drug treatment has been proposed to increase along with increasing BMI
(63).
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Clinical trials
   It was shown in a recent review of the randomised trials of weight reduction in overweight
hypertensive subjects that a weight loss of from three to nine percent was associated with
a decrease of 3 mmHg in both SBP and DBP (64). The efficacy of even modest weight
reduction in the prevention of hypertension has also been documented in overweight subjects
with high normal BP (21, 65, 66). In one study, however, a weight loss of 20 kg following
gastric surgery did not have any effect on the 8-year incidence of hypertension (67).
   It has been shown in both middle-aged and elderly subjects that weight reduction may
substitute antihypertensive drug treatment in a sizable part of the hypertensive patients (68,
69). In addition, some studies have demonstrated that weight loss combined to the
antihypertensive drug treatment is significantly more effective in control of hypertension
compared to drug treatment alone (70, 71).
The mechanisms of obesity-induced hypertension
   Obesity and especially abdominal obesity is suggested to increase BP by several
mechanisms (72, 73). These mechanisms include increased sympathetic activity caused by
increased caloric intake and hyperinsulinemia, increased renal sodium reabsorbtion due to
hyperinsulinemia, impaired peripheral vasodilatation due to the peripheral insulin resistance
and possibly reduced endothelium-dependent vasodilatation caused by obesity-induced
dyslipidaemia. Interestingly, it has also been shown that in a subset of hypertensive
population high BP precedes the gain of weight (60). Based partly on this finding, it has been
proposed that both the BP elevation and weight gain may reflect the primary increase in
sympathetic tone (74). According to this theory, the decrease in b-adrenergic responsiveness
established in hypertensive subjects with increased sympathetic activity could lead to
diminished energy expenditure and thereby to inevitable weight gain.
2.3.3.2  Sodium intake
   Sodium is a mineral found all around in nature. In industrialised countries, over 80 % of the
sodium intake originates from the sodium chloride added to food. The association between
sodium intake and BP has been recognised for a long time although the strength and
importance of the association is still widely debated (75).
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The measurement of sodium intake in epidemiological studies
   For research purposes, the best method for assessment of sodium intake is the measurement
of sodium excretion from a single 24-hour urine sample (76).  It has been estimated that
77-86 % of the ingested sodium is excreted to urine (77). Due to relatively large day-to-day
variation in sodium output, multiple collections are needed for assessment of the sodium
intake of an individual person (78). However, single 24-hour urine collections are reliable in
estimating the mean or median sodium excretion of the population (79).
The preliminary epidemiological studies
   The first epidemiological studies plotting the data of salt intake against hypertension
prevalence in various populations demonstrated the linear positive association between these
two variables (80-82). In these studies, it was found that a 100 mmol extra daily intake of
sodium (~5.8 g sodium chloride) was associated with an 8-9 mmHg rise in SBP and with
a 4-5 mmHg rise in DBP. Primarily the same data used in these studies was analysed further
in a meta-analysis by Law et al. in 1991 (83). Their analysis yielded principally the same
results, but in addition, demonstrated that the impact of sodium intake on BP in subjects aged
60-69 years was twice of that than in subjects at age 15-19 years. Similarly, they showed that
the predicted change in BP was greatest in the upper end of the BP distribution. However,
these studies were objected to major criticism because of the varied methodology in
assessment of sodium intake and BP, as well as for not controlling the possible confounding
variables. These serious limitations resulted in a launching of a major international
collaboration, the INTERSALT study in the mid 80's (84).
The INTERSALT study
   The INTERSALT study was conducted in altogether 52 study centres, in 32 countries
worldwide with a sample of 10 079 men and women aged 20-59 years. Data collection
methods were highly standardized and the investigators went through careful training before
the fieldwork was started. It was found in pre-defined within-population analyses of the study
that there was an independent association between 24-h urinary sodium excretion and SBP
(25). In further analyses with multivariate correction for regression dilution bias SBP was
estimated to be on average 3.1-6.0 mmHg and DBP 0.1-2.5 mmHg lower with 100 mmol/day
smaller sodium intake depending whether BMI was included or not into the multivariate
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analysis (85). The association was more pronounced at age-group 40-59 years compared to
the younger age group. In between populations-analyses, 100 mmol higher sample median
24-hour urinary sodium excretion was associated with on average by 5-7/2-4 mmHg higher
SBP/DBP and with 6.2 % higher prevalence of hypertension. The estimated mean difference
in SBP/DBP with this difference of sodium excretion at age 55 compared with age 25 was
greater by 10-11/6 mmHg demonstrating the impact of sodium in age-related rise in BP level
found in all western societies. The four INTERSALT populations with very low sodium
excretion had low median blood pressures, low prevalence of hypertension, and no significant
increase of blood pressure with age – the finding shown also by many other previous
ecological studies of isolated populations still following a more or less traditional hunter-
gatherer lifestyle (86, 87).
Clinical trials
   The most compelling evidence of the causal relationship between the salt intake and
hypertension originates from experimental studies in animals and from randomised trials of
sodium supplementation and restriction in humans. In a controlled study by Denton et al. in
the normotensive chimpanzees with a low-sodium diet rich in fruits and vegetables, the
increase in salt intake to 5 grams/day caused a 12 mmHg rise in SBP by 19 weeks (88). The
further increase of salt intake to 15 grams/day to 62 weeks caused a rise of 33 mmHg in SBP
and of 10 mmHg in DBP. The BP of the experimental group reverted to the baseline level 20
weeks after reinstitution of the original diet. Salt supplementation studies done in humans
have been of shorter duration. In a randomised trial assessing the impact of salt intake on BP
during the first 6 months of life in infants, SBP at 6 months was 2.1 mmHg higher in the
group assigned to higher salt intake compared to control group (89). Fifteen years later, the
group fed with more salt had still 3.6 mmHg higher SBP than the control group, indicating the
possibility of long-term effects of salt intake during infancy (90). In a meta-analysis of
randomised controlled salt supplementation trials in hypertensive adults, a high salt diet
produced on average an increase of 5.6 mmHg in SBP and an increase of 3.5 mmHg in DBP,
respectively (91).
   The most recognized meta-analyses of clinical trials of salt restriction show a reduction of
3.7-5.8 mmHg in SBP and of 0.1-2.3 mmHg in DBP of hypertensive subjects for a 100 mmol
reduction in 24-hour urinary sodium excretion – the results depending of the inclusion criteria
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of the trials (20, 92-94). In these meta-analyses, the effect of sodium reduction in BP was
larger in elderly subjects compared to younger subjects and somewhat smaller in
normotensive subjects compared to hypertensive population. After publishing of these meta-
analyses, two landmark studies of sodium restriction have been reported. The first one, called
TONE (Trial of Nonpharmacologic Interventions in the Elderly) including 681 patients aged
60-80 years showed that a 40 mmol/day reduction in 24-hour urinary sodium excretion for
a mean follow-up time of 28 months was accompanied by a net decrease of 4.3 mmHg in SBP
and of 2.0 mmHg in DBP, respectively (95). Along with the observed reduction in DBP, also
the need for antihypertensive drug therapy could be significantly reduced. In the “DASH II”
study (Dietary Approaches to Stop Hypertension) 412 subjects with or without hypertension
were randomised to a diet typical in the United States or the DASH diet, which is rich in
vegetables, fruits and low-fat dairy products (96). Within the assigned diet, the participants
consumed foods with high, intermediate and low sodium content for 30 days each, in
a random order. The results showed that both the DASH diet and the reduced sodium intake
reduced significantly and independently both SBP and DBP. The effect of sodium reduction
of 100 mmol/day in the control diet was 6.7 mmHg in SBP and 3.5 mmHg in DBP in
hypertensive participants. The reductions in BP were even larger in black hypertensive
subjects, and somewhat smaller but still significant in normotensive subjects.
   The effect of reduced sodium intake on BP has also been studied in many clinical trials
assessing the independent and combined effects of sodium restriction and antihypertensive
drug treatment in hypertensive subjects. The evidence from these studies show that the
restriction of sodium intake enhances significantly the BP-lowering effect of beta-blockers,
diuretics and angiotensin-converting enzyme (ACE) inhibitors (97-99).
   The data from the studies aiming to reduce salt intake in the general population show that
the long-term compliance to a low-salt diet is difficult to achieve (100). The North Karelia
Salt Project was started in 1979 in eastern Finland to assess the feasibility and effects of salt
reduction in the population of North Karelia (101). The results of the programme were
compared with the neighbouring county, Kuopio. The intervention programme aiming to
increase the common knowledge of the adverse health effects of excess salt intake lasted for
three years. The local health care personnel and home economics teachers who were trained
by the dieticians provided health education. The local press and radio was also used. After
three years of intervention, the population mean salt intake, assessed at the baseline and at
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three years by 24-hour urine samples, did not change significantly except in normotensive
women. Similar results were also reported in a community survey in Belgium (102).
Salt sensitivity
   As demonstrated in many studies, there is quite a marked individual variation in BP
response to salt restriction (103). In studies of drastic salt restriction, BP falls in a proportion
of subjects, increases in others and remains unchanged in the rest of the population. On the
other hand, BP rises in virtually everyone, if large amount of salt is supplemented even for
a short time (104). It has been proposed that this "salt sensitivity", defined usually as an
arbitrary cut-off point of 10 mmHg change in mean BP after salt loading or depletion, is more
prevalent in hypertensive than in the normotensive population (50-70 % vs. 26-36 %) (103),
in blacks compared to other races (104), in elderly than in the young (105) and in the obese
compared to subjects with normal weight (106). The suggested pathophysiologic mechanisms
accounting for salt sensitivity include low plasma renin activity (107), increased sensitivity of
the sympathetic nervous system (108) and insulin resistance, especially in obese subjects
(109). So far, no clinical test with good reproducibility has been invented for salt sensitivity.
From a population perspective, however, it has been claimed that the vast majority of the
population are more or less sodium sensitive (84).
Pathophysiology of salt-induced hypertension
   The exact mechanisms by which excess sodium intake induces BP to rise are still somewhat
unclear. The main hypotheses include the volume expansion associated with the defect in the
excretory function of the kidneys, increased activity of the sympathetic nervous system and
the increase in intracellular calcium concentration (110).
Other health-related effects of excessive sodium intake
   Independent of its effect on BP, high salt intake has been shown to be a predictor for left
ventricular hypertrophy (LVH) and dysfunction, renal disease, decreased vascular
compliance, stroke, osteoporosis and stomach cancer (111-114). In addition, in a recent
Finnish prospective study with 2436 men and women, a positive association between a high
24-hour urinary sodium excretion and the incidence of CHD was demonstrated for the first
time (115). The finding of this study was in a strong discordance with two previous studies
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published by Alderman et al. (116, 117), which suggested an increased risk of myocardial
infarction among subjects with low sodium intake. However, these two American studies
have been an object of a great deal of criticism because of serious flaws in the methodology
used in the assessment of salt intake (118).
2.3.3.3  Alcohol consumption
Observational studies
   The independent positive association between alcohol intake and BP has been found in
many cross-sectional population-based studies (119). It has been suggested in these studies
that both SBP and DBP rise steadily when alcohol intake increases beyond two drinks
(26 g of pure alcohol) per day, and that there is no further increase in BP when alcohol intake
exceeds six drinks per day (120). This association has been documented as more linear in men
than in women, in whom the relationship has been found to be more or less "J-shaped"
(121, 122). The prevalence of hypertension (>160/95 mmHg or antihypertensive drug
treatment) has been approximately twofold in subjects consuming six or more drinks per day
compared to subjects with 0-2 drinks per day.  It was shown in the second Kaiser Permanente
study that the alcohol-BP relationship was stronger in men than in women, in whites than in
blacks and in subjects aged 60 or more (121). It was also found that this relationship existed
only in subjects consuming alcohol daily. In addition, the choice of alcohol beverage did not
have a significant impact on this relationship. In the multinational INTERSALT study, SBP
was 3-4 mmHg and DBP 2-3 mmHg higher in subjects consuming 240 g of alcohol
(21 standard drinks) per week compared with subjects consuming less than that or with
abstainers (123).
   The role of alcohol intake as a predictor of elevated BP, independent of other well-known
risk factors for hypertension, has been established in many prospective epidemiological
studies (124-128). Some studies suggest that the alcohol-induced increase in BP has been
stronger in SBP than in DBP (129) and in black than in white subjects (128). The suggested
threshold value for the association between alcohol intake and hypertension in these studies
has varied between two and three standard drinks of alcohol per day.
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Clinical trials
   The effect of changes in alcohol intake on BP has been shown in many crossover and
randomised, controlled trials (32, 130-132). These trials have demonstrated the acute pressor
effect of alcohol intake on BP at the level of three to eight drinks per day, as well as the short-
term decrease in BP following reduction of alcohol ingestion by three drinks per day. These
effects have been demonstrated in both normotensive and hypertensive subjects, and they
have been independent of weight loss, sodium restriction or exercise (133-135). In a recent
meta-analysis, the restriction of alcohol consumption was associated with a decrease of
3.31 mmHg in SBP and of 2.04 mmHg decrease in DBP, respectively (136). In this study, a
clear dose-response relationship between alcohol restriction and BP reduction was observed.
The observed reductions in BP were greatest in those with the highest baseline BP. The same
effects of alcohol abstinence on BP have been also demonstrated using 24-hour ambulatory
BP monitoring (137). So far, the results from studies assessing the long-term effects of
alcohol restriction on BP have been negative (138).
   According to some studies, the regular alcohol consumers seem to respond less well to
antihypertensive drug treatment (139). This finding is possibly a consequence of diminished
compliance with the treatment regimens found in this patient-group (140).
Possible mechanisms for alcohol-induced hypertension
   There are many hypothetical mechanisms by which alcohol intake could increase BP. The
suggested mechanisms include the increase in plasma catecholamine, renin, cortisol and
intracellular calcium levels causing vasoconstriction, tachycardia and increased heart rate
variability (32, 141-144). Some studies suggest that the observed effect of alcohol intake on
BP could be due to a physiological withdrawal reaction related to acute alcohol abstinence
just before the medical examinations (120, 145). However, also opposite findings have been
reported (146).
   The evidence from both observational and interventional studies suggests that the alcohol-
induced pressor effect on BP is rapidly reversible (147, 148). Similarly, in the studies
comparing the effects of binge and daily drinking on BP, it has been shown that the effects of
regular drinking are more sustained than that of "binging" (149, 150). However, also the BP
rise related to regular drinking is found to be reversible.
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Other health-related effects of excess alcohol use
   According to many large-scale studies, moderate drinking (1-2 drinks per day) has a slight
protective effect against CHD (151). In contrast, more severe drinking has been shown to be
an independent risk factor for cardiomyopathy, haemorrhagic stroke (152) and all-cause
mortality (151). The increased risk of ischaemic stroke in young adults has been suggested to
be related especially to binge drinking (153) during the weekend and holiday times (154),
possibly due to rapid changes in BP associated with this type of alcohol intake (155).
2.3.3.4  Physical activity and fitness
Observational studies
   The results of the several large cross-sectional studies examining the relationship BP and
either physical activity or physical fitness are somewhat inconsistent. Many population-based
studies have, after adjusting with age and other confounders, reported of the inverse
relationship between these variables (156-160). In these studies, the adjusted difference in
both SBP and DBP between the most and least physically active has averaged 5 mmHg (161).
According to some studies, however, the observed differences in BP have become
insignificant after adjusting with the other lifestyle variables (162, 163).
   It has been shown in some prospective studies that physical activity and fitness are inversely
and independently related to later development of hypertension (164-166). In these studies,
the relative risk for elevated BP has been reported as 1.5-1.9 times higher in the least fit
compared to the fittest subjects (165, 166). In addition, a low physical fitness has been
documented as an independent risk factor for all-cause mortality in hypertensive men (167).
Some studies have suggested that the changes in physical activity or fitness have been
inversely related with the changes in SBP in women (168, 169).
Clinical trials
   The independent BP-lowering effect of aerobic training has been documented by several
reviews (161, 170, 171) and meta-analyses of clinical trials (22, 172). In a meta-analysis
including 29 randomised controlled trials lasting 4 weeks or longer (mean 18.9 weeks, range
4-52 weeks), it was reported that aerobic exercise training reduced resting SBP by 4.7 mmHg
(95% confidence interval, CI 4.4 to 5.0 mmHg) and DBP by 3.1 mmHg (95 % CI 3.0 to
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3.3 mmHg) (22). Additionally, the results of this meta-analysis suggested that observed BP
reduction was independent of the intensity of exercise (mean 62 % of the maximal oxygen
uptake, VO2 max, range 30-87 % VO2 max) and of the number of exercise sessions per week
(mean 3.2 sessions). The authors concluded that increasing exercise intensity above 70 %
VO2 max or increasing exercise frequency to more than three sessions per week did not any
further impact on BP. The results of a meta-analysis of 54 randomised controlled trials
published just recently by Whelton et al. were in accordance with these findings (173).
The effect of exercise on BP has been reported to be equally great in both hypertensive and
normotensive subjects in all but one review that also included  non-randomised trials (161).
   The evidence of the impact of progressive resistance exercise on resting BP is still
inconclusive. In a recent meta-analysis of the randomised controlled trials lasting four weeks
or more, a pooled decrease of 3 mmHg (95 % CI -4 to -1) could be detected in both SBP and
DBP (174). However, as mentioned by the authors, the low methodological quality of many
studies did not justify for making very firm conclusions about the importance of this kind of
training in non-pharmacological treatment of hypertension
The antihypertensive mechanisms of exercise
   The decrease in BP induced by endurance training may be explained by decreased stroke
volume and contractility of the heart after exercise (175) combined with the decreased
systemic vascular resistance (176) - both phenomena caused possibly by decreased
sympathetic activity. The other suggested mechanisms include reduced levels of plasma renin
activity and catecholamines (177), as well as increased urinary sodium excretion and insulin
sensitivity (178). It has been shown in the studies using ambulatory BP measurement that
these acute haemodynamic effects caused by aerobic exercise exist only in hypertensive
subjects and that they are of limited duration (179). This finding may explain the need for
continuous regular exercise to maintain the favourable effects achieved on BP level in
hypertensive persons.
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2.3.3.5  Potassium intake
Observational studies
   Potassium intake, assessed by 24-hour urinary potassium excretion or by 24-hour dietary
recall, has been shown to be inversely related with BP in many cross-sectional within
population-studies (25, 180-183). In the INTERSALT study, after adjustment for potential
confounders, an increase in potassium excretion of 50 mmol/day was associated with the
decreases of 2 mmHg in SBP and of 1.5 mmHg in DBP (25). These relationships between
either SBP or DBP and potassium excretion were stronger than those with sodium excretion.
However, as documented also in some other observational studies, the ratio of urinary sodium
to potassium correlated even more closely to BP than either electrolyte excretion individually
(184). It has been speculated that these measured associations between urinary electrolyte
excretions and BP within population-studies are underestimations of the true relationships
because of the great intraindividual day-to-day variation in the urinary output of electrolytes
(78).
Clinical trials
   There are so far two published meta-analyses of the trials assessing the effects of potassium
supplementation on BP (185, 186). It was estimated in the latter one of these studies,
including 33 randomised controlled trials in both normotensive and hypertensive subjects, that
a 53 mmol/day increase in potassium intake was associated with a mean decrease of
3.11 mmHg in SBP (95 % CI 1.91 to 4.31 mmHg) and of 1.97 mmHg decrease in DBP
(95 % CI 0.52 to 3.42 mmHg), respectively (186). It was shown in this meta-analysis, that the
treatment related-reductions in both SBP and DBD were significantly higher in the studies
including subjects with mean 24-hour urinary sodium excretion greater than 165 mmol per
day compared with the subjects with sodium excretion less than that. Based on this finding,
the authors concluded that increased potassium intake should be considered for prevention
and treatment of hypertension especially in subjects unable to reduce their high intake of
sodium. The controlled studies of the effects dietary intake of potassium on BP are rare, but
the results of these studies are in accord with those of the supplementation studies (187, 188).
   The suggested mechanisms by which a lack of potassium could elevate BP include
vasoconstriction induced by the increases in intracellular calcium concentration (189),
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increase in sympathetic activity (190), increased release of renin (191) and the retention of
sodium (192).
2.3.3.6  Dietary fat intake
Observational studies
   The association between BP and different types of dietary fat has been investigated in
several cross-sectional studies in various populations. Most of these studies have found no
relationship between BP and intake of saturated, monounsaturated, polyunsaturated or trans
fatty acids. However, some population-based studies in Finland and United States have
reported of positive correlations between BP and the intake of saturated fats, even after
adjustment for possible confounders (193, 194). Correspondingly, some studies have
suggested an inverse relationship between the intake of polyunsaturated fats and BP or
between the ratio of polyunsaturated to saturated fat intake and BP (194-196).
The prospective studies assessing the incidence of hypertension in relation to intake of any
type of fat intake have failed to show any association (126, 197).
Clinical trials of the effects of dietary fat manipulation on BP
   The effect of manipulation of dietary fat intake on BP has been investigated in numerous
intervention studies. The impact of dietary fat modification was assessed in three separate
Finnish studies with crossover design in 1981-1983 (198-200). During the intervention period
of these studies, the total fat intake was reduced from 39 % to 24 % of the total energy intake
and the ratio of polyunsaturated to saturated fat intake was increased from 0.2 to 0.4-1.2. Both
SBP and DBP decreased significantly during the intervention periods, and the BP values
returned to the initial levels during the switchback period. The observed decrease in SBP/DBP
in the intervention groups of these studies was 7-8/3-5 mmHg in normotensive subjects and
4-10/4-6 mmHg in hypertensive subjects. When the data of these studies were pooled, the
multiple regression analyses including weight and other dietary variables suggested that the
increase in polyunsaturated fatty acid intake was the strongest predictor of BP change (201).
However, all the other trials except one Finnish study (202) reported since then have failed to
repeat this finding (203-205). It has been criticized that the interpretation of the results of
these Finnish and also many other studies with manipulation of dietary fat is difficult, because
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the changes in fat intake were accompanied by other dietary changes possibly affecting BP
(206). For this reason, few studies have used a basal diet supplemented with n-6
polyunsaturated fatty acids (207, 208). These studies have also not detected any significant
association between changes in BP and type of fat intake. It has been suggested that this
inconsistency between the studies could be related to the baseline ratio of polyunsaturated to
saturated fat intake. This hypothesis originates from the finding that in all the studies with
positive results the baseline ratio was less than 0.3 whereas the ratio was more than that in all
the studies with negative results (209). According to the evidence, the changes in the intake of
monounsaturated or trans fatty acid have no significant influence on BP (210), although the
increased intake of trans fatty acids is recently suggested to contribute to some extent to the
risk of CHD (211).
Clinical trials of fatty acid supplementation and BP
   The effects of dietary supplements of n-3 fatty acids, eicosapentanoic and docosahexanoic
acid - found especially in fish, on BP have been summarized in two meta-analyses including
17 (212) and 31 (213) placebo-controlled trials, respectively. In the former study, the pooled
effect on SBP/DBP was -1.0/0 mmHg in normotensive subjects and -5.5/-3.5 mmHg in
hypertensive subjects, respectively. The average dose of n-3 fatty acid supplementation in this
review was 1 g/day. In the latter study, there was no significant change in BP of the
normotensive subjects, but the reduction in SBP/DBP in hypertensive subjects with the
supplement intake of on average 5.6 g/day was 3.4/2.0 mmHg. In this study, a significant
dose-response relationship between fish oil supplementation and BP was observed. In one
controlled study comparing the effects of daily fish meal (3.4 g n-3 fatty acids) to either 5 or
10 g fish oil supplements on BP, the decrease in BP was similar in all groups with increased
n-3 fatty acid intake (214). Accordingly, it was shown in double-blind placebo-controlled
Norwegian study that fish oil supplementation of 6 g per day did not have any influence on
BP among the subjects with at least three fish meals per week (215). It has been suggested
that of the two n-3 fatty acids derived from fish, docosahexanoic acid may be more effective
in 24-hour BP reduction compared to eicosapentanoic acid (216). The BP-lowering effects of
n-3 fatty acids are possibly amplified by weight reduction (217). In addition to the effect on
BP, it has been suggested that the n-3 fatty acids may decrease the risk for CHD even at
moderate level of fish consumption (218).
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Antihypertensive mechanisms of fatty acids
   The possible antihypertensive mechanisms of the increased ratio of the polyunsaturated to
saturated fats include an increase in vasodilator prostaglandin synthesis and improved
endothelial dilator function due to reduced serum Low density lipoprotein (LDL) cholesterol
levels (219, 220). The suggested antihypertensive effects of the n-3 fatty acids are likely due
to increased endothelial vasodilatation, reduced vascular smooth muscle contractility and
possibly also to a decrease in heart rate (215, 221).
2.3.3.7  Other environmental factors
   In addition to lifestyle factors listed above, there is also some evidence of the association
between a few other environmental factors and BP. These factors include birth weight,
smoking, coffee ingestion, intake of some other nutrients than already mentioned in this
review, socio-economic status, migration and psychological stress.
Birth weight
   The independent inverse association between the birth weight and SBP during both
childhood and adult life has been verified in many epidemiological studies. In these studies,
a 1 kg increase in birth weight has been associated with decrease of 1-4 mmHg in SBP in
children, adolescents and adults (222, 223).  It is hypothesized that fetal undernutrition caused
by maternal undernutrition would play a crucial role in the development of this association.
According to the "fetal origins" hypothesis, this would lead to intrauterine ”programming”
causing structural, physiological and metabolic changes in the fetus affecting the levels of BP
and other cardiovascular risk factors in later life (224). In contrast, the results from twin
studies emphasize that placental dysfunction could be the major cause for retarded
intrauterine growth leading to the elevated SBP (225, 226). The impact of retarded
intrauterine growth on incidence of hypertension is reported to be even stronger in the
subjects with accelerated postnatal growth (227). The suggested mechanisms for the
association between low birth weight and elevated BP include the programming of the fetal
hypothalamic-pituitary axis leading to higher fasting cortisol levels in adults (228), increased
sympathetic activity (229) and impaired renal development (230). The data from some studies
show that the effect of low birth weight on BP is strongest in those with the highest BMI as
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adults (231). This observation suggests that the prevention of obesity is especially important
among the children and adults with low birth weight.
Smoking
   It has been shown in several clinical studies that smokers present higher 24-hour BP levels
than their non-smoking counterparts (232, 233). This association is mediated probably by
nicotine - the most detrimental element of the tobacco smoke for the cardiovascular system.
The acute nicotine-induced effects of smoking are 1) the rise in sympathetic activity leading
to increase in heart rate, cardiac out-put and peripheral vasoconstriction (234); and 2) the
increase in plasma cortisol and aldosterone levels (235). In contrast to the results of these
clinical studies, the most epidemiological surveys have demonstrated equal or even lower BP
levels in smokers compared to non-smokers, even after adjustments for BMI and other risk
factors for hypertension (236, 237). This paradoxical finding has been attributed to the fact
that in large epidemiological studies BP is measured casually and the participants are not
permitted to smoke within a certain period before the measurements. Therefore, the possible
acute rise in BP during smoking could not be observed (238). Surprisingly, it was reported in
a recent large 4-year follow-up study including 8170 healthy men that smoking cessation was
associated with increased risk of hypertension (239). This association was independent of the
changes in body weight and the risk was attenuated with the increased length of the period of
cessation. In short, taking account the current evidence from epidemiological studies, the
chronic effect of smoking on BP is likely to be small. Still, the effect of smoking on
cardiovascular risk among hypertensive subjects is of major importance and will be discussed
later in this review.
Coffee drinking
   The effect of coffee consumption on BP was assessed in a meta-analysis comprising
11 controlled clinical trials with a median duration of 56 days (240). According to this study,
SBP/DBP increased by 2.4 /1.2 mmHg more in the group consuming on the average 5 cups of
coffee/day compared to the control group. Accordingly, a significant coffee-induced increase
in both ambulatory SBP and DBP was reported in a recent trial in older subjects with
hypertension, but not in normotensive subjects (241). In addition, in one case-control study
assessing the relationship of coffee consumption and smoking on ambulatory BP, the
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ambulatory SBP was reported to especially high in smokers consuming at least four cups of
coffee per day, suggesting an additive interaction between these two variables (242). The
results of these short-term studies are not in accord with the findings of a recent American
prospective study with a median follow-up of 33 years (243). In this study, consumption of
one cup of coffee a day raised SBP by 0.19 mmHg (95 % CI 0.02 to 0.35 mmHg) and DBP by
0.27 mmHg mmHg (95 % CI 0.15 to 0.39 mmHg). The relative risk for the development of
hypertension was not significant in subjects drinking coffee at least five cups a day compared
to coffee abstainers. Therefore, it can be concluded that according to the current evidence the
long-term effects of coffee drinking on BP are relatively small.
Intake of calcium, protein, magnesium and fibre
   The data from the observational studies show no consistent association between dietary
calcium and BP (244). However, the results of the two meta-analyses of the intervention
studies assessing the effect of calcium supplementation on BP show that 1150-1300 mg dose
of calcium regimen reduced SBP in hypertensive subjects by 1.7-4.4 mmHg (245, 246).
According to the limited evidence, also the increase in dietary intake of protein, magnesium
and fibre may lower BP (126, 247, 248).
Sosioeconomic status and mental stress
   In developed countries, there have been studies reporting of the association of a lower
socio-economic status with high BP (249, 250) In contrast, in developing countries this
association is documented to be vice versa, i.e., mean BP is highest in the subjects with higher
socio-economic status (251). These associations are explained mainly by the differences in
well-established lifestyle factors affecting BP across the socio-economic groups (252). The
same explanation seems to account for the rise in BP level demonstrated in migration studies
with the subjects moving from the rural areas to areas with more "westernised" societies
(253). In the migration studies, the environmental stress is hypothesised to be one of the key
factors in the initiation of the BP rise, although the evidence of the efficacy of stress
management in treatment of hypertension is lacking (254, 255)
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2.3.3.8  Trials of the effects of lifestyle intervention on blood pressure in primary health
             care
   As reviewed above, there is sufficient evidence to suggest that certain changes in nutrition
and physical activity can decrease BP in subjects with hypertension. This evidence comes
from the intervention studies organised in carefully controlled clinical conditions in academic
study centres. What is less clear, however, is how to achieve these changes in lifestyle in
primary health care as a part of routine management of hypertension (256). So far there are
a limited number of randomised, primary prevention trials assessing the effects of lifestyle
intervention in primary health care with BP as one of the outcome variables. The majority of
these trials have been targeted subjects with increased cardiovascular risk (257-259), the
population as a whole (260, 261) or families (262, 263). In an analysis using pooled data of
these studies, the net difference in SBP/DBP reduction between intervention groups and usual
care was 2.3/1.3 mmHg (264). In this analysis, studies with antihypertensive drug treatment
were excluded. The randomised controlled trials assessing the impact of lifestyle changes on
BP solely among subjects with hypertension in a primary care setting are rare. These studies
are listed in Table 2. In three of these trials, the intervention was based on individual lifestyle
counselling (265-267) and in one on group sessions (268). The three studies based on
individual counselling could be characterized as pilot studies with a relatively small number
of patients and short duration of follow-up. Therefore, the results of these studies are difficult
to apply to every-day clinical practice. In contrast, it was demonstrated in a Japanese study
(268) that community-based health education given in a group setting can effectively reduce
SBP in patients with hypertension. In this study, the reduction in SBP was attributed mainly
to the reduction in sodium and alcohol intake.
2.4   Hypertension and cardiovascular risk
2.4.1  The evidence from the epidemiological studies
   Several large-scale epidemiological studies in various parts of the world have demonstrated
the strong positive association between elevated BP and the incidence of atherosclerotic
cardiovascular diseases (1, 2, 269, 270). It was summarized in a review of these studies that
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Table 2. Randomised controlled trials of efficacy of non-pharmacological treatment of hypertension in primary health care.
Reference, country Participants Inclusion criteria Number of
participants
Intervention Duration of
follow-up
Net difference in BP
(mmHg) between
intervention and control
groups
(265), Netherlands Men and women,
screened in one general
practice, mean age
45 years
DBP 90-109 mmHg, no
history of CHD, diabetes
and antihypertensive
drug treatment,
BMI < 27
35 3 individual
counselling sessions by
nutritionist
3 months SBP: -2.8 (p=0.17)
DBP: -2.0 (p=0.15)
(266), USA Men and women,
screened in one health
care centre, mean age
60 years
SBP >140 mmHg or
DBP > 90 mmHg and
BMI > 27.8 in males and
> 27.3 in females
30 Monthly counselling
sessions by GP
12 months MAP: 3.7 (p>0.1);
SBP and DBP: NA
(267), Australia Men and women,
screened  from 13
general practices, mean
age 58 years
Drug treatment for
hypertension
166 Low intervention
group: one appointment
with a nurse and five
15 min telephone
counselling sessions;
High intervention
group: Six
appointments with
a nurse
4.5 months SBP: -6  (p<0.05);
DBP: -5 (p<0.05)
(268), Japan Men and women,
screened from
community-based
program for stroke
prevention; mean age
59 years
SBP 140-179 mmHg
and/or DBP 90-109
mmHg, no
antihypertensive drug
treatment, no target-
organ disease
111 7 group meetings
conducted by
physician, nutritionist
and public health nurse.
18 months SBP: -5.8 (p=0.04);
DBP: 0.4 (p=0.41)
MAP, mean arterial pressure; NA, not applicable
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a long-term difference of 5-6 mmHg in casual DBP was associated with reductions of
35-40 % and 20-25 % in the incidences of stroke and CHD, respectively (269). In the 36-year
follow-up data of Framingham Study, the risk ratios in hypertensive men (SBP > 140 mmHg
or   DBP > 90 mmHg) aged 35-64 years were 2.0 for CHD, 3.8 for stroke, 2.0 for peripheral
artery disease and 4.0 for cardiac failure compared to their normotensive counterparts (2). The
corresponding risk ratios in women were 2.2, 2.6, 3.7 and 3.0, respectively. In addition,
elevated BP is documented as one of the main predictors of LVH, a strong independent risk
factor for cardiovascular events (271, 272). Elevated BP is also consistently documented as an
important precursor for end-stage renal disease (273). The relationship between BP and these
disease outcomes has been documented in both men and women and in all age-groups as
graded, i.e. the higher the BP level the higher the risk, and as continuous with no actual
threshold value below which there would be no risk (1). This continuum of risk was just
recently clearly demonstrated by the Framingham Study investigators, who showed that the
risk ratio for major CVD events in the subjects with even high normal BP
(130-139/85-89 mmHg) was 2.5 in women and 1.6 in men compared to subjects with optimal
BP (<120/80 mmHg) (274).
   According to many observational studies, SBP is more closely related to cardiovascular risk
than DBP (275, 276). In the Framingham study, the incidence of CVD events was
substantially greater in subjects with isolated systolic hypertension compared to subjects with
isolated diastolic hypertension and more or less the same than in subjects with combined
systolic and diastolic hypertension. Therefore, it has even been suggested that in persons with
SBP elevation, knowledge of the level of DBP is of limited use in cardiovascular risk
assessment (2). This strong, positive association between isolated systolic hypertension and
CVD events has been verified especially in studies of elderly subjects (277, 278), but it
applies also to the middle-aged population (279, 280). Studies comparing the pulse pressure
(the difference between SBP and DBP) and SBP as independent variables in predicting CVD
events in middle-aged subjects have yielded inconsistent results (281, 282). On the contrary,
the respective studies in the elderly have found pulse pressure to be a better predictor of CVD
than SBP (283).
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The pathophysiology of accelerated atherosclerosis associated with hypertension
   The exact mechanism by which elevated BP enhances the development of atherosclerotic
diseases is not yet well defined. However, there is some evidence that hypertension
predisposes to and accelerates atherosclerosis in co-operation with other atherogenic risk
factors by exerting oxidative stress on arterial wall (284). This oxidative stress may activate
endothelial genes which are involved in generating an inflammatory response that, especially
in presence of hyperlipidaemia, leads to the formation of atheroscletoric plaques.
2.4.2  Antihypertensive drug trials
   The benefits of antihypertensive drug treatment in prevention of cardiovascular events
associated with malignant hypertension were recognized in the early 60's. The Veterans
Administration Trial was the first trial to demonstrate the efficacy of antihypertensive drugs
in prevention of cardiovascular events among middle-aged subjects with less severe
hypertension (285). The results of this trial comparing the hydrochlorthiazide/
reserpine/hydralazine-based treatment to placebo in subjects with baseline DBP
115-129 mmHg were published in 1967. In this study, active treatment was associated with
significant reduction in the incidence of stroke and total cardiovascular events, but not in the
incidence of myocardial infarction. Since then, several large trials comparing usually diuretic-
or beta-blocker-based treatment with placebo have been conducted in middle-aged subjects
and also in elderly subjects with a DBP of 90-115 mmHg. In a systematic review of these
trials, including 37 000 patients with mean treatment duration of 5 years, it was concluded
that a 5 mmHg difference in DBP reduced stroke incidence by 42 % and CHD incidence by
14 %, respectively (3). In this review, the relative risk reduction associated with
antihypertensive drug treatment was of the same magnitude in all individuals, irrespective of
the age of the participants.
   The increasing evidence of the hazards associated with elevated isolated systolic
hypertension, the most common type of hypertension among the elderly, resulted in
a launching of studies assessing the effects of antihypertensive drugs in this subgroup of
hypertensive subjects older that 60 years (286-288). In a recent meta-analysis the data from
these studies were combined with the data of the subgroup of elderly subjects with isolated
systolic hypertension enrolled in five other trials primarily of systolic-diastolic hypertension
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(289). In this review, active treatment leading to a fall of 10.4 mmHg in SBP and of
4.1 mmHg in DBP reduced total mortality by 13 %, cardiovascular mortality by 18 %, all
cardiovascular events by 26 %, the incidence of stroke by 30 % and all coronary events
by 23 %.
   Some studies suggest that there could be a J-shaped relationship between mortality and on-
treatment DBP in hypertensive patients with evidence of CHD, i.e. those with the highest and
lowest on-treatment DBP have the highest mortality risk. This increased risk in the subjects
with low DBP has been speculated to be due to decreased coronary perfusion associated with
overaggressive reduction of DBP (290). However, according to accumulated evidence from
randomised trials and observational studies, the lowering of BP to a level of 140/85 mmHg
and even lower will produce the greatest reduction in cardiovascular complications
(291, 292). In these studies, the CVD risk reduction was greatest in subjects with greatest BP
reduction irrespective of the baseline BP level. It has been suggested that the possible
explanation for increased mortality in the patients with the lowest DBP observed in some
studies could be related with deterioration of the general health independent of
antihypertensive drug treatment or that the low DBP is a consequence of underlying CHD
(293, 294).
   The studies assessing the association between the BP lowering and the reduction of
cardiovascular events before 90's were mainly based on treatment with beta-blockers or
diuretics - "the older" type of antihypertensive drugs. Since then the newer classes of
antihypertensive drugs, i.e. calcium-channel blockers and ACE inhibitors, have been
investigated and compared with the older classes of antihypertensive drugs in different
aspects of hypertension management. Based on these studies, it has been concluded that there
are on average no significant differences between the antihypertensive drug classes in terms
safety or efficacy in terms of BP reduction or CVD prevention (71, 295, 296). However, this
conclusion was just recently challenged by the results of the LIFE (Losartan Intervention For
Endpoint reduction in hypertension) study (297). In this randomised trial with 9193
participants having both hypertension and LVH, the CVD risk reduction associated with BP
reduction induced by losartan, an angiotensin-II type 1-receptor antagonist, was compared to
the risk reduction induced by atenolol, a well-known b-blocker from the previous large-scale
studies. The results of the study showed that the number of CVD events and CVD deaths was
significantly smaller in the losartan group compared with the atenolol group. This finding did
42
not change significantly when the small difference in BP reduction between the groups was
taken into account in the analyses. Based on these findings, the authors concluded that, at
least in this high-risk group of hypertensive subjects, the treatment of high BP with losartan
can offer benefits that are beyond the BP reduction.
2.4.3 The effects of other risk factors on cardiovascular risk in subjects with
hypertension
   The relative cardiovascular risk reduction associated with antihypertensive drug treatment,
as reviewed in the previous paragraph, is found to be relatively constant regardless of other
cardiovascular risk factors or characteristics of the subject. In contrast, the effect of
antihypertensive drug treatment on absolute cardiovascular risk is more dependent of the level
of other cardiovascular risk factors, age of the subject and of the presence or absence of the
target-organ damage than on the absolute BP level of the subject (298, 299). It has been even
argued, that treatment of mild hypertension in subjects with no other cardiovascular risk
factors could do more harm than good (300). Therefore, the treatment decisions in latest
guidelines for hypertension management are based on estimated absolute cardiovascular risk
for the individual patient instead of pure BP levels (15, 16). In the following, the most
important factors affecting the CVD risk in subjects with high BP will be reviewed.
2.4.3.1  Age and gender
   In the 36-year follow-up data of the Framingham study, the cardiovascular disease risk ratio
among hypertensive men and women aged 65-94 years compared to normotensive subjects of
the same age group was 1.8 (14). This risk ratio was somewhat smaller than the
corresponding ratio in hypertensive subjects aged 35-64 years. This decrease in relative risk
for CVD events along with the increasing age is offset by the striking increase in the CVD
incidence in the elderly. This makes the absolute cardiovascular risk associated with
hypertension greater in this age group compared to the younger age groups with the same BP
level. Accordingly, the relative CVD risk reduction observed in antihypertensive drug trials
including only elderly subjects with systolic or diastolic hypertension has been of similar size
to those seen in trials with younger subjects. However, the absolute benefits observed in the
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elderly subjects have been more than twice as great as those observed with the younger
subjects (301). So far, the evidence of the benefits of antihypertensive drug treatment is
limited to subjects aged up to 80 years. Currently, a new trial is recruiting hypertensive
subjects aged 80 years or more to investigate the effects of BP-lowering therapy in this
patient-group (302).
   According to the Framingham data, the relative risk for CVD events is very similar in both
genders (14). However, the absolute risk in men up to 64 years was almost twofold compared
to that of women. This difference in absolute CVD risk between the sexes was halved in
subjects older than that.
2.4.3.2  Smoking
   The data of the large observational studies show that cigarette and cigar smoking are
powerful predictors of CHD and ischaemic stroke in the general population (303, 304). These
studies have also indicated that this risk decreases sharply in those who quit, especially in the
middle-aged and younger population (303). In hypertensive subjects, cigarette smoking
increases the CVD risk for any level of BP. The Framingham data suggest that the risk for any
CVD event is almost twofold in a hypertensive 50-year-old male patient who smokes
compared to his non-smoking counterpart (305). In a study among the drug-treated
hypertensive patients, the total 5-year mortality was 2.3 times higher in smokers compared to
non-smoking patients (306). Correspondingly, in both middle-aged hypertensive men and
women who smoke 20 cigarettes per day, quitting smoking will reduce the CVD risk by 35-40
% during the next two years (305).  It has been estimated that 70-80 % of the expected benefit
in terms of CVD risk reduction from simultaneous treatment of hypertension and smoking
cessation can be attributed to smoking cessation (307). The additive effects of smoking as
a CVD risk factor is mediated by the increase in formation of atherosclerotic lesions (308), as
well as by increased thrombus formation and detrimental effects on the haemostatic system
(232). In addition, smoking can reduce the BP-lowering effect of some antihypertensive
drugs, especially non-selective b-blockers (309, 310). Smoking also probably worsens the
lipid profile especially among those with drug treatment for hypertension (311, 312).
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2.4.3.3  Dyslipidaemia
   A large body of evidence derived from observational studies shows that high serum
concentrations of total and LDL cholesterol, as well as the low levels of serum High density
lipoprotein (HDL) cholesterol are associated with increased CHD risk (313, 314). In these
studies, a 0.6 mmol/l decrease in total cholesterol was associated with 54 % reduction in CHD
risk in men aged 40 years, whereas the similar fall in cholesterol in men aged 70 years could
produce a CHD risk reduction of 20 %, respectively. Similarly, a 0.03 mmol/l increase in
HDL-cholesterol was associated with at least a 3% reduction in CHD risk at all ages. Some
epidemiological studies suggest that the elevated ratio of total to HDL cholesterol is
a stronger predictor of CHD incidence than either of these variables alone (315). The benefits
of total and LDL cholesterol reduction by statin treatment in the primary and secondary
prevention of CHD have been demonstrated in several trials (316-319). In these trials, the net
reduction in CHD events has varied between a fifth and a third.
   In the hypertensive screenees (DBP > 90 mmHg) of the large Multiple Risk Factor
Intervention Trial (MRFIT) study, the CHD death rate was 5.14 times higher in hypertensive
subjects with total cholesterol > 6.34 mmol/l compared to normotensive subjects with
a cholesterol value of less than 4.71 mmol/l (320). In the pooled data of the treated
hypertensive men of the Gothenburg Primary Prevention study, the 8-year risk for all CVD
events were approximately fourfold in subjects with no change in SBP or in total cholesterol
during the follow-up compared to subjects with 20 % reduction in SBP and 11 % reduction in
total cholesterol (321). In this study, the effect of SBP reduction on CVD and CHD events
was very small if serum cholesterol levels remained unchanged. The subgroup analyses of the
statin trials demonstrate the similar relative benefits of treatment both in normotensive and
hypertensive subjects in CHD prevention (318).  In a few years, the data of two large
on-going trials will be available to demonstrate the possible absolute benefits of statin
treatment in drug-treated hypertensive patients without CHD (322, 323).
2.4.3.4  Type 2 diabetes
   Type 2 diabetes is a well-established independent risk factor for CHD, stroke and peripheral
vascular disease (324, 325). It has even been reported that diabetic patients without previous
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history of CHD have as high a risk for myocardial infarction as non-diabetic subjects with
previous myocardial infarction (325). The risk for CVD events is already significantly higher
in subjects with pre-diabetic levels of hyperglycaemia compared to normoglycaemic subjects
(324, 326). In subjects with type 2 diabetes, the increase in CVD risk associated with
co-existing hypertension is significantly greater than that observed in non-diabetic subjects,
suggesting an effect more than additive (327). It has been proposed that the risk for CVD
events is approximately fourfold in subject with both type 2 diabetes and hypertension
compared to non-diabetic normotensive subjects (328).
   The effects of antihypertensive drug treatment on CVD morbidity and mortality in
hypertensive patients with type 2 diabetes have been studied in many randomised clinical
trials. Based on the studies with a pre-specified DBP target level, it has been concluded that
the benefits of tight BP control in reduction of CVD risk and total mortality in this patient-
group are even greater than in hypertensive subjects in general (291, 329, 330). These
findings have been taken into account in the latest guidelines for management of
hypertension, which recommend somewhat lower target BP in diabetic hypertensive patients
than in hypertensive subjects without diabetes (15-17, 35). The potential of BP reduction
especially in this patient-group has also been shown in a subgroup analyses of  three separate
placebo-controlled trial assessing the effects of antihypertensive drug treatment on isolated
systolic hypertension (331-333). The benefits of different antihypertensive drug classes in
hypertensive diabetic patients have been compared in subgroup analyses of many recent trials
(330, 334-338).  In most of these trials, there were no differences in the CVD risk reduction
between these different drug classes (330, 334, 336, 337). However, the results of the CAPPP
(the Captopril Prevention Project) and just recently published LIFE studies suggest that the
ACE inhibitor- or angiotensin-II type 1-receptor antagonist-based treatment could offer more
efficient cardiovascular protection than the conventional treatment with b-blockers and
diuretics in hypertensive patients with type 2 diabetes (335, 338).
2.4.3.5  Obesity
   The positive independent association between obesity and the incidence of CHD has been
shown in many epidemiological studies (339, 340). This association has been demonstrated as
linear, starting already within the normal BMI range, i.e. in subjects considered to have
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a normal weight. Also the weight gain during adulthood, even within the normal weight
range, has been found to be a strong predictor for CHD (341, 342). In contrast, in most of the
studies including only hypertensive subjects the risk for CHD and CVD mortality has been
significantly higher among lean subjects compared to their obese counterparts (343-346),
although also some opposite findings exist (347). It has been suggested that this excess in
CHD mortality among lean hypertensive subjects could be explained by different and "more
severe" pathophysiology and haemodynamics of hypertension in these subjects compared to
the obese hypertensives (346). However, in addition to the importance of obesity as a
predictor of hypertension, it has been shown that elevated BP is an important risk factor for
CVD and all-cause mortality also in obese subjects (346, 348). Therefore, the concomitant
treatment of hypertension and obesity in overweight subjects with high BP is important.
2.5 Community control of hypertension
2.5.1 Rationale
   The effective prevention of the diseases preceded by high BP at the population level
requires a two-tailed approach. The first approach aims to identify those subjects in the
population who have their BP already on hypertensive level and to control their BP by non-
pharmacological means and also by drug treatment if warranted (15, 16). This approach is
called ”the individual approach” and reaches only the minority of the population.
   In populations, the BP values are distributed more or less in the normal manner with a slight
dominance of higher values (349). In the western populations, this distribution curve and
mean BP are shifted to the right at older ages. The steeper this rise along increasing age is, the
higher is the population mean BP. Due to the continuous nature of the BP distribution the
prevalence of hypertension increases in conjunction with the increase in the population mean
BP. This increase in BP along with the age is apparent in most populations with a westernised
lifestyle, but virtually absent in some remote populations with healthier lifestyle patterns.
Therefore, it has been suggested that the main reason for these large differences between the
populations in the position of BP distribution curve and so, in the mean BP and prevalence of
hypertension are mainly due to the large differences in the environmental factors affecting BP
(85).
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   In the western populations, the main proportion of the BP readings is located within the
normal or high normal range (120-129/80-84 mmHg or 130-139/85-89 mmHg).  Although the
risk for CVD associated with elevated BP is continuous and progressive along with the
increasing BP values, the largest number of CVD events in the population occurs in this
category due to the large number of subjects with their BP at this level. According to the
hypertension guidelines, the vast majority of these patients should not be treated with
antihypertensive drugs, at least partly because it would not be by no means cost-effective.
Therefore the only possibility to lessen the CVD burden in this BP category and at the same
time in the majority of the population is to shift the entire BP distribution of the population to
the left towards lower BP values by detecting and modifying the environmental factors
affecting BP. This strategy is called the ”population approach” because in this strategy the
target for intervention is the whole population.
   Both strategies mentioned above are important and complementary. However, the
”population approach” carries a larger potential for decreasing the sequeale of hypertension in
community, and at the same time it offers the possibility for primary prevention of
hypertension (2). For instance, according to just recently published findings of the
Framingham study, 37 % of the subjects with high normal BP aged 65 years or less became
hypertensive over 4 years of follow-up (350). In this study, one of the main predictors for the
development of hypertension was weight gain of 5 % or more. The results of the study
emphasise the importance of adequate follow-up and modification of unfavourable lifestyle
factors in these subjects. It has been estimated that in most of the western populations only
a 2-3 mmHg decrease in population mean SBP could reduce the prevalence of hypertension
by one fifth and the annual mortality rate from stroke and CHD by 6 % and 4 %, respectively
(351, 352). To investigate the situation and the trends with respect to both of these strategies
in the population, the monitoring of independent random samples of the target population is
a feasible approach.
2.5.2 Prevalence, awareness, treatment and control of hypertension in the community
   In 1972, Wilber and Barrow published their classic paper of a community control of
hypertension in which the term "rule of halves" was introduced for the first time (353).
According to this rule, only half of the hypertensive subjects are detected, and half of those
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who are detected are under antihypertensive drug treatment, of whom only half have their BP
controlled adequately. These results demonstrating the poor situation of hypertension control
at the population level were soon confirmed in population surveys also in other parts of the
world (354, 355). These findings were adopted as the basis for the many population-based
hypertension control programmes starting in the early 70´s. The main targets of these
programmes were the early detection and effective drug treatment of hypertension. Since the
implementation of these population-based programmes, some improvement in these various
aspects of hypertension control have taken place.
   In a review by Marques-Vidal and Tuomilehto 24 population surveys of hypertension
awareness, treatment and control published since 1983 were assessed (356). In men, the rates
for hypertension awareness, antihypertensive drug treatment among the detected
hypertensives and control of BP among drug-treated hypertensive subjects varied from 23 %
to 93 %, from 5 % to 89 % and from 5 % to 97 %, respectively. The corresponding figures in
women were from 28 % to  97 %, from 6 % to 97 % and from 0 % to 97 %. On the average,
in the industrialized countries the vast majority of the hypertensive subjects were aware of
their condition, two thirds of those aware of their high BP were treated with antihypertensive
drugs and half of those treated had their BP at a normotensive level. The rates for awareness,
treatment and control were somewhat better in women than in men. Conversely, in the
developing countries, as confirmed also by another recent review (357), the situation was
more or less the same as in the industrialised countries at the time the "rule of halves" was
invented. Also in these countries, the rates for different aspects of hypertension management
were higher in women than in men.
   In contrast to the relatively high number of published reports of single cross-sectional
samples assessing the situation in hypertension management at the population level, there are
relatively few studies assessing the evolution of hypertension care in the same population.
Such studies published in English-language journals are listed in Table 3. These studies, if
using similar field methods in each survey, are suitable for the assessment of trends in
hypertension care in the same population.
   In Finland, as in most other western countries, a favourable development in hypertension
care has been reported (8, 358). This development started along with the establishing of the
hypertension programme of the North Karelia Project in 1971 (359). The specific aims of the
programme were to detect as many of the hypertensive subjects as possible, to control BP as
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efficiently as possible in these subjects, to create uniform and appropriate methods in
hypertension management among the physicians and to gather data on hypertension
epidemiology (359). During 1972-1977, a significant improvement in detection and
management of hypertension was observed. In next five years, the situation in hypertension
care was maintained, but no further reduction in population BP levels was seen (8). During
1982-1987, a significant reduction in population SBP levels and to some extent also in
hypertension care especially among men took place (358). However, the situation in 1987 was
reported as far from optimal.
   The variability of the cut-off points chosen for the definition of hypertension affects
strongly the epidemiological estimates of hypertension (367). This fact can be easily seen also
in table 3 where the different cut-off points are used between and within the studies. Also the
different methodology used in BP measurements makes the international comparisons
difficult. These aspects were taken account in the WHO MONICA project with highly
standardised methodology in BP measurements and with a uniform definition for
hypertension (10). When 41 MONICA study populations were ranked by descending levels of
age-adjusted SBP measured between 1982 and 1987, the Kuopio province in Eastern Finland
was ranked first in both sexes (9).  In men, the difference between the Kuopio province and
Catalonia of Spain was 24 mmHg (148 mmHg-124 mmHg). In women, the SBP of women in
Kuopio was 27 mmHg higher than in women in Halifax, Canada (145 mmHg-118 mmHg),
who had the lowest mean SBP of the WHO MONICA populations. With the WHO MONICA
criteria for hypertension (SBP > 160 mmHg and/or DBP > 95 mmHg or antihypertensive drug
treatment) the rates for prevalence of hypertension in those aged 35-64 years in Kuopio were
approximately fivefold in men and threefold in women compared to the survey participants  in
Catalonia (368)
2.5.3 The prevalence of other cardiovascular risk factors in hypertensive subjects
   The data from the studies reviewed here which assess the levels of one or several other
cardiovascular risk factors in hypertensive subjects originate from random samples of the
target population (18, 369, 370), from all the available subjects or subsample of subjects in
a defined geographical area (19, 371) or from the hypertensive screenees in the primary health
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Table 3. Population-based studies of trends in community control of hypertension.
Country,
reference
Criteria for
hypertension*
Age-
range,
years
Gender Study
years
Prevalence of
hypertension
(%)
Awareness of
hypertension
(%)
Drug-
treated
(%)
Drug-
treated of
aware
(%)
Controlled
(%)
Controlled
of drug-
treated (%)
Australia, (360) 1 Combined 1980 31 67 33 49 17 52
1983 30 77 33 43 19 58
Belgium, (361) 1 25-64 Men 1980-84 20 49 26 53 15 58
1985-92 13 67 47 71 31 65
Women 1980-84 19 66 48 73 28 60
1985-92 13 88 74 83 62 84
England, (362) 1 > 16 Men 1994 19 60 45 75 27 60
1998 20 68 54 79 37 68
Women 1994 20 66 54 83 32 58
1998 20 74 64 86 40 63
2 Men 1994 41 33 20 60 5 23
1998 42 40 26 64 8 31
Women 1994 35 46 32 69 7 23
1998 33 52 38 73 11 28
Finland1, (8) 3 30-59 Men 1972 30 39 13 33 4 31
1982 26 67 45 66 23 51
Women 1972 35 66 28 42 6 27
1982 21 82 57 67 27 47
Finland, (358) 3 25-64 Men 1982 18-242 70 42 60 23 55
1987 14-222 79 51 65 29 57
Women 1982 12-192 85 61 72 39 64
1987 14-172 87 65 75 41 63
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France, (363) 1 35-64 Men 1985-87 28 47 38 81 16 41
1994-97 21 71 57 80 33 58
Women 1985-87 19 67 57 85 25 44
1994-97 19 87 76 87 52 68
Germany, (364) 1 25-64 Men 1984-85 19 66 32 48 17 55
1994-95 20 75 46 61 28 61
Women 1984-85 14 83 56 67 34 61
1994-95 15 82 60 73 42 69
2 Men 1984-85 38 48 16 33 5 30
1994-95 39 55 24 44 7 29
Women 1984-85 25 66 32 48 10 31
1994-95 25 66 38 58 15 39
Taiwan, (365) > 18 Combined 1976 14 32 26 81 5 19
1982 15 74 42 57 5 12
USA, (366) 1 18-74 Men 1976-80 21 59 37 NA 18 49
1988-91 15 85 72 NA 57 80
Women 1976-80 19 78 62 NA 40 63
1988-91 14 93 86 NA 72 84
2 Men 1976-80 37 42 21 NA 5 24
1988-91 23 66 46 NA 22 50
Women 1976-80 27 63 43 NA 15 36
1988-91 18 81 65 NA 38 58
*1=SBP > 160 mmHg or DBP > 95 mmHg or antihypertensive drug treatment, 2=SBP > 140 mmHg or DBP > 90 mmHg or antihypertensive drug treatment,
3= SBP > 175 mmHg or DBP > 100 mmHg or antihypertensive drug treatment; 1 North Karelia province; 2Variation between the study areas; NA, not
applicable
52
care or occupational health clinics (13, 372-375). In only two of these studies were the time
trends in these risk factors assessed (369, 370).
   The common features of the studies comparing the lipid levels or prevalence of lipid
abnormalities between hypertensive and normotensive subjects have been a significantly
higher prevalence of hypercholesterolaemia amongst hypertensive persons and significantly
lower HDL cholesterol among the drug-treated hypertensive patients compared to
normotensive subjects. For instance, in a large population-based random sample of men and
women aged 25-64 years in Australia, the prevalence of hypercholesterolaemia (total
cholesterol > 6.5 mmol/l) in untreated hypertensive men and women were 57 % and 94 %
greater compared to their normotensive counterparts  (28.5 % vs. 18.1 % in men and 37.0 vs.
19.1 in women, p-values<0.001) (18). The level of HDL cholesterol in drug-treated
hypertensive men and women was significantly lower compared either to normotensive or to
the untreated hypertensive group. Furthermore, the ratio of total to HDL cholesterol was
significantly higher in the drug-treated hypertensive patients compared to the other groups in
men, but not in women. At least part of the observed low levels of HDL cholesterol among
the treated hypertensive patients participating the population-based studies is suggested to be
due to the adverse effects on lipid metabolism caused by antihypertensive drug treatment -
especially treatment with diuretics and b-blockers (370). However, these findings have not
been confirmed in long-term clinical trials comparing the effects of different antihypertensive
drug regimens on lipid profile (376).
   In contrast to other cardiovascular risk factors reviewed, the prevalence of smoking in most
of the hypertensive populations is not significantly different from that of general population.
For example, in the screenees of the MRFIT study, the prevalence of smoking was 37.7 % in
hypertensives and 34.5 % in normotensives (372). In the Tromssr Heart study the prevalence
of smoking in men and women with antihypertensive drug treatment was 28 % and 9 %,
whereas the corresponding figures in normotensive men and women were 35 % and 13 %,
respectively (19). In contrast to these findings, there were significantly fewer smokers among
the drug-treated hypertensive subjects in both sexes compared to normotensive population in
a large Finnish population-based sample among those aged 35-64 years in 1982 (24.9 % vs.
38.7 % in men, 8.1 % vs. 16.4 % in women) (369).
   The mean BMI, and the prevalence of obesity and type 2 diabetes are consistently reported
to be significantly higher in the hypertensive subjects attending the primary care clinics
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compared to their background population (373-375). In the hypertensive population of
Gubbio study, the prevalence of obesity was approximately twofold in both sexes up to age of
64 years compared to the normotensive subjects (371).
   The changes in levels of cardiovascular risk factors in Finnish hypertensive subjects aged
35-64 years during 1982-1987 were assessed in two random population-based samples as a
part of the FINMONICA study (369). During the five-year period, the mean serum
cholesterol decreased in treated hypertensive men and women by 2 % and 4.7 %, respectively.
The mean serum HDL-cholesterol increased by 4.5 % and 9.9 % in these same groups. In
contrast to these favourable findings, the prevalence of smoking tended to increase and mean
BMI increased significantly, especially in men with antihypertensive drug treatment.
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3  AIMS OF THE STUDY
3.1  General aim
   The purpose of this study was to assess the trends in community control of hypertension in
Finnish population samples aged 25-64 years, with special interest in cardiovascular risk
factors of hypertensive subjects. Another aim was to examine in  a randomised, controlled
trial if BP and other cardiovascular risk factors of hypertensive subjects could be affected in
primary health care setting by non-pharmacological means.
3.2   Specific aims
1. To describe the trends in blood pressure levels and in prevalence, awareness and
control of hypertension in various parts of Finland during 1982-1997 (STUDY 1).
2. To compare the trends in serum lipids, BP, smoking, diabetes, BMI and obesity,
waist circumfererence, alcohol consumption and leisure-time physical activity in
hypertensive population during 1982-1997 with those of the normotensive
population (STUDY 2).
3. To assess the efficacy of a lifestyle-counselling programme planned for hypertensive
subjects in a randomised controlled clinical trial conducted in ten health care centres
in eastern Finland (STUDY 3).
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4  METHODS
4.1 Community control of hypertension (STUDIES 1 and 2)
4.1.1 Study populations
   A multinational MONICA project was initiated by the WHO in 1982 (10). The
FINMONICA study was the Finnish part of this project. The FINMONICA survey areas since
1982 were the provinces of North Karelia and Kuopio in eastern Finland and the Turku-
Loimaa region in southwestern Finland. In 1992, the Helsinki-Vantaa region was included in
the study areas and since that the surveys have been carried out under the name of the
National FINRISK Study to indicate their role in national cardiovascular risk factor
monitoring. In 1997, the monitoring was started also in the Oulu region (Figure 2).
   Four independent cross-sectional population surveys were carried out in 1982, 1987, 1992
and in 1997. The survey methods followed the WHO MONICA protocol each year (377). The
random samples aged 25-64 years were chosen each year from the national population
register. In 1982, the sample was stratified so that 500 persons for each sex and 10-year age
group were chosen in the areas. In 1987, the procedure was similar, but the number of
subjects in Kuopio and Turku-Loimaa region was halved. Since 1992, the number of subjects
was halved also in North Karelia province so that the samples were of equal size in each area.
4.1.2 Data collection
Questionnaire
   Information on awareness of hypertension and hypercholesterolaemia, use of
antihypertensive drugs, smoking behaviour, disease history, alcohol use and leisure-time
physical activity were obtained with a standardised, self-administered questionnaire. The
question about diagnosed diabetes was analysed in the present study since 1987.
Correspondingly, the use of lipid-lowering drugs was asked since the 1992 survey. The
participants were classified to following categories according to their smoking behaviour:
(I) current smokers (those who had smoked regularly cigarettes,  cigars or pipe for at least one
year and had been smoking during the preceding month), (II) ex-smokers  (those who had
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Figure 2.  Survey areas in studies 1 and 2. Modified from (378).
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smoked regularly in the past but had stopped smoking no later than a month before the
survey) and (III) never smokers (those who had never smoked regularly).
BP measurement and criteria for hypertension
   Specially trained nurses measured BP in each survey. These nurses were circulated between
the study areas to eliminate the possible observer bias in the between-areas comparisons.
BP was measured twice from the right arm of the subject, who was seated for five minutes
before the measurement. A standard mercury sphygmomanometer with a cuff bladder 13 cm
wide and 42 cm long was used. The fifth phase of the Korotkoff sounds was used as the
diastolic pressure, and the values were recorded to the nearest 2 mmHg. The mean of these
two measurements was used in the analyses. In Study 1, two different cut-off points for
hypertension were used: SBP/DBP > 160/95 mmHg and SBP/DBP > 140/90 mmHg. With
both these criteria, the subject was considered hypertensive if he or she reported having taken
antihypertensive drugs during the preceding seven days. In Study 2, only the higher cut-off
point was used.
Anthropometrical measurements and classification of overweight
   Weight was measured with light clothing and height was measured without shoes. Waist
circumference was measured in the surveys since 1987. It was measured from the midway
between the inferior margin of the last rib and the crest of the ileum, as recommended by
WHO (379). BMI was used as a measure of relative body weight. Participants were divided
into four classes according to their BMI following the classification by WHO:
BMI < 25 kg/m2 (normal weight), BMI 25-29.99 kg/m2 (grade 1 overweight), BMI 30-39.99
kg/m2 (grade 2 overweight) and BMI > 40 kg/m2 (grade 3 overweight) (379).
Lipoprotein determinations and criteria for hypercholesterolaemia
   Non-fasting serum total and HDL cholesterol concentrations after the precipitation of
b-lipoproteins with dextran sulphate and magnesium chloride were determined using an
enzymatic method (CHOD-PAP, Boehringer Mannheim, Germany) (380). A new batch of
Dextran Sulphate Sodium Salt (Pharmacia, Sweden, Lot No MM 97012) for precipitation of
ApoB containing lipoproteins was introduced in the laboratory on May 1987. However, the
HDL cholesterol values with the new precipitant were approximately 4.4 % lower than those
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measured with the old precipitant. Therefore the results measured before May 1987 were
corrected using the following formula: HDLcorrected = ((HDLold - 1.2621)/0.3592) * 0.3230) +
1.1969. After this correction, the average and standard deviation of the sample results were
the same as those measured using the new precipitant. All lipoprotein determinations were
made in the same central laboratory, and the laboratory data were standardized against the
WHO reference laboratory in Prague. Hypercholesterolaemia was defined as the serum total
cholesterol > 6.5 mmol/L or if having drug treatment for hypercholesterolaemia. The ratio of
total to HDL cholesterol was considered as high when the ratio was greater or equal to five.
4.1.3 Study designs
   The designs of Studies 1 and 2 are presented in Table 4. In trend analysis of the community
control of hypertension (Study 1), the data were analysed in all five study areas separately.
The total number of participants during 1982-1997 was 29,036 (Table 5). In Study 2, all three
original FINMONICA study areas (the North Karelia and Kuopio provinces and the region of
Turku-Loimaa) were pooled together, and the Helsinki-Vantaa and Oulu region were left out
from the analyses. The study population was classified into four groups according to their BP
status: Unaware and untreated hypertensive subjects, aware but untreated hypertensive
subjects, hypertensive patients treated with antihypertensive drugs and normotensive subjects.
The total number of participants was 24,083, with participation rates varying from 69 % to
75 % in men and from 76 % to 82 % in women, respectively. The number and mean age of
subjects in each BP group are shown in Table 6.
4.1.4 Statistical methods
   Statistical analyses were conducted with the SPSS/PC+ in Study 1 and SPSS for Windows
version 7.5 in Study 2. In Study 1, analysis of variance was used as a statistical method to
test the differences between the BP means in each gender separately, with SBP and DBP as
dependent variables, area and year as independent variables and age as a covariate.
Differences between the proportions were assessed by hierarchical log-linear model with year
and area together with the variable to be tested within the model.
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Table 4. Designs of studies 1 and 2.
Study
years
Study
areas
Subjects Number
of
subjects
Explanatory
variables
Outcome variables Type of
study
Study 1 1982-
1997
North
Karelia,
Kuopio,
Turku-
Loimaa
Men and
women aged
25-64 years
29,036 Study year, area SBP, DBP; prevalence, awareness, treatment and
control of hypertension; prevalence of
antihypertensive drug treatment
Cross-
sectional
trend
analysis
1992-
1997
Helsinki-
Vantaa
1997 Oulu
Study 2 1982-
1997
North
Karelia,
Kuopio,
Turku-
Loimaa
Men and
women aged
25-64 years
24,083 Study year,
blood pressure
group
Total and HDL cholesterol, SBP, DBP, BMI,
waist circumference; prevalences of
hypercholesterolaemia, smoking, obesity and
diabetes;  alcohol use, leisure-time physical
activity
Cross-
sectional
trend
analysis
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Table 5. Number of participants (N) and participation rates (%) by gender, year and area
 in Study 1.
Study area and year Men Women
N % N %
North Karelia province
1982 1538 76 1681 83
1987 1561 79 1689 85
1992 673 68 803 81
1997 712 71 751 75
Kuopio province
1982 1475 80 1349 86
1987 793 80 857 86
1992 752 76 830 84
1997 707 71 799 80
Southwestern Finland
1982 1602 81 1702 86
1987 755 76 824 83
1992 749 75 832 84
1997 683 68 747 75
Helsinki-Vantaa region
1992 675 68 737 74
1997 631 63 716 72
Oulu region
1997 663 66 750 75
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Table 6. The number (N, %) and mean age of the participants according to gender, year and the BP group in Study 2.
Hypertensive Normotensive All
Untreated and unaware Aware but untreated Treated with drugs
N   (%) Age
(years)
N   (%) Age
(years)
N   (%) Age
(years)
N   (%) Age
(years)
N (%) Age
(years)
Men
1982  688 (15.3) 48.1  440  (9.8) 46.1  411  (9.1) 52.8 2960 (65.8) 41.9 4499  (100) 44.3
1987  373 (13.0) 47.1  290 (10.0) 48.3  314 (10.9) 53.1 1901 (66.1) 42.8 2878  (100) 45.2
1992  199  (9.2) 50.3  198  (9.2) 50.1  240 (11.1) 53.6 1525 (70.5) 42.8 2162  (100) 45.3
1997  140  (6.8) 47.9  194  (9.4) 49.6  254 (12.3) 54.6 1472 (71.5) 43.2 2060  (100) 45.6
Women
1982  329  (7.1) 53.7  403  (8.7) 50.1  507 (11.0) 55.6 3373 (73.1) 42.0 4612  (100) 45.2
1987  207  (6.6) 53.4  238  (7.6) 49.2  366 (11.6) 55.0 2336 (74.2) 42.0 3147  (100) 44.9
1992  108  (4.4) 53.3  175  (7.1) 51.5  239  (9.7) 55.1 1934 (78.8) 42.7 2456  (100) 45.0
1997   65  (2.9) 53.3  132  (5.8) 49.8  230 (10.1) 55.3 1842 (81.2) 43.0 2269  (100) 45.0
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    In Study 2, analysis of variance was used to test the differences between the total
cholesterol and HDL cholesterol means for each sex separately, with total and HDL
cholesterol as dependent variables, BP group and study year as independent variables and age,
body mass index and alcohol use as covariates. Correspondingly, the differences between the
BP and BMI means for each sex separately were tested with SBP, DBP and BMI as
dependent variables, BP group and study year as independent variables and age as a covariate.
Differences between the proportions were assessed by a hierarchical log-linear model with
year, BP group and 10-year age group together with the variable to be tested within the
model. Confidence intervals for the change between the years in means of continuous
variables and in proportions for each gender and BP group separately were calculated using
a special software package (381).
4.2 Non-pharmacological treatment of hypertension in primary health care  (STUDY 3)
4.2.1 Screening and randomisation of the participants
   The LIHEF study  (Lifestyle Intervention against Hypertension in eastern Finland) was
conducted in ten primary health centres in eastern Finland. Eight of the health centres were
located in rural municipalities with 3000-12,000 inhabitants (the health centres of Eno,
Kiihtelysvaara, Kitee, Kontiolahti, Lieksa, Liperi, Nurmes and Pyhäselkä). The remaining two
health centres were located in the cities of Joensuu and Kuopio which have 50,000 and 90,000
inhabitants, respectively (51 % of all participants). The study protocol was approved by the
Ethics Committee of the Kuopio University Hospital. The study participants were enrolled
between February 1996 and May 1997. Vast majority of the participants were recruited by
newspaper advertisements. Eligible subjects were men and women aged from 25 to 74 years
with systolic BP 140-179 mmHg or diastolic BP 90-109 mmHg or patients on
antihypertensive drug therapy. Exclusion criteria included secondary hypertension, mental or
physical illness serious enough to prevent compliance with the study procedures, alcoholism,
type 1 diabetes mellitus, current or planned pregnancy and history of myocardial infarction or
stroke within the preceding 3 months.
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   Three screening visits in one-week intervals were organised to assess the BP level of the
subjects not using any antihypertensive medication. During each screening visit BP was
measured twice from the right arm of the subject in a sitting position according to the WHO
MONICA protocol using a standard mercury sphygmomanometer with a cuff bladder 12 cm
wide and 36 cm long (382). The mean of the BP measurements performed in the second and
third visit (a total of four readings) was used as the screening BP. The randomisation visit was
organised within 30 days after the third screening visit. A written informed consent was
obtained from every eligible subject agreeing to participate after which they were randomised
to intervention or usual care by the same study physician using a dice (odd numbers-
intervention group, even numbers-control group). Of the 813 subjects originally eligible for
the study, 715 were eventually assigned to intervention or usual care.
4.2.2 Data collection
   The design of the Study 3 is presented in Figure 3. BP, weight and waist and hip
circumferences were measured from every participant during the randomisation visit, the
1-year visit and at the final study visit 2 years after randomisation. During these visits, BP
was measured twice using the same method as during the screening and the mean was used in
the analyses. Weight was measured with the subjects in light clothing using the same digital
scale. Height was measured only at the baseline. BMI (kg/m²) was calculated. Waist
circumference was measured with the same method as in Study 2. The circumference of hip
was measured from the maximum extension of the buttocks.
   Most of the BP and anthropometrical measurements during the screening and follow-up
period were performed by one study nurse trained for the trial and blinded to the treatment
assignment. However, in 176 participants of one health centre, the second study nurse did the
measurements  during the screening and randomisation visits. During the training period, the
mean BP of ten volunteers did not differ significantly between the nurses when a double
stethoscope method was used.
   The venous blood samples were collected after 12 hours of fasting in each health centre for
determination of serum total and HDL-cholesterol, triglycerides and insulin. All laboratory
analyses were performed in the Department of Biochemistry, National Public Health Institute,
Helsinki, Finland. Before April 1 in 1998, total cholesterol, HDL cholesterol and triglycerides
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Figure 3. The design of the study 3. PN= public health nurse, FFR=feedback from the food record, GM=group meeting, other abbreviations in
page 9. *Usual care group visited their own public health nurses as usual.
RANDOMISATION
Usual care*
Intervention
FOLLOW-UP,
MONTHS
PN, FFR
PN
PN,
GM
PN FFR PN PN,
GM
PN
MEASUREMENTS
AT BASELINE,
12 MONTHS AND
24 MONTHS:
BP
Weight
Height (only at baseline)
Waist
Hip
Total cholesterol
HDL cholesterol
LDL cholesterol
Triglycerides
24-hour urinary sodium excretion
24-hour urinary potassium excretion
Insulin
Questionnaires
4-day Food record
0 1 3 6 9 12 15 18 21 24
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were determined using the same commercial kit (Boehringer Mannheim GmbH, Germany)
and Olli C analyser (Kone Ltd, Espoo, Finland). Total cholesterol was determined by an
enzymatic GPO-CHOD-PAP method and triglycerides by a GPO-PAP method, respectively.
HDL cholesterol was determined by an enzymatic CHOD-PAP method after the precipitation
of b-lipoproteins with dextran sulphate and magnesium chloride. After April 1 in 1998, total
cholesterol and triglycerides concentrations were determined using the same enzymatic
method of another company (Konelab Corporation, Espoo, Finland). The HDL cholesterol
concentration was determined using a direct method of this same company. There were no
significant differences between the lipid values given by the two different laboratory methods
and analysers. LDL cholesterol concentrations were calculated by Friedewald’s formula
(383). Twenty-four-hour urine samples were collected for determination of 24-hour potassium
and sodium excretion. The urine was collected in plastic containers or in throwaway
containers. The containers were returned at the health centre to the study nurse, who
ascertained the completeness of the collection. Urinary sodium and potassium concentrations
were determined potentiometrically using the direct ISE method (Ion-Selective Electrodes).
   Information on medical history, smoking, alcohol use, physical activity and daily
medication were collected annually using separate questionnaires with standard questions
used also in Studies 1 and 2.  A four-day food record was collected for the annual visits. The
detailed information of the dietary methods and results are published elsewhere (384).
4.2.3 Intervention goals and methods
   The goals for the intervention were 1) to achieve normal weight (BMI < 25 kg/m²) if
overweight, 2) to reduce a 24-hour sodium intake to less than 85 mmol (< 5 g sodium
chloride), 3) to modify alcohol consumption to no more than two drinks per day if using
more, 4) to exercise at moderate intensity at least three times per week and at least to 30
minutes and 5) to stop smoking if a smoker.
   Before the launching of the study, the study physician and a dietitian carried out a teaching
session to the local public health nurses in each health care centre separately. The training
session dealt with simple counselling and behaviour modification methods targeting weight
reduction, reduction in salt, alcohol and saturated fat consumption, and increasing leisure time
physical activity.
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   The core of the actual intervention consisted of four visits by the participants to local public
health nurses during the first year of the follow-up, and of three visits during the second year
(Figure 3). At these visits, the participants were instructed to change their health behaviour
primarily based on their individual situation. At every visit, BP and weight were measured
and the values were written down using a special follow-up card. A written feedback of the
four-day food record was sent to the public health nurse to support the intervention. In
addition, six and 18 months after the randomisation, a two-hour group session was organized
in every health care centre for the intervention group by a dietitian and the study physician.
During the two-year follow-up, the participants in the usual care group were instructed to visit
the public health nurses and their own physicians according to usual practices.
4.2.4 Statistical analyses
   Statistical analyses were conducted with SPSS for Windows version 10.0. For continuous
variables, t-test was used to test the differences and changes in mean values between the
groups. Confidence intervals for the differences in proportions were calculated using a special
software package (381). An intention to treat-analysis was used, i.e. all subjects assigned to
intervention or usual care were included in the analysis. In case of missing responses, the last
observed response was used when calculating the one- and two-year changes in continuous
variables (the carry forward-method). The same method was used with dichotomous
variables. In a separate analysis of BP changes in subjects without previous antihypertensive
drug treatment, the last BP measurement without antihypertensive drug treatment was used if
drug treatment was initiated during the trial. Accordingly, in subjects already on
antihypertensive medication, the last BP measurement with antihypertensive drug treatment
was used if the treatment was discontinued during the trial. In the calculations of BP changes,
the changes in doses of antihypertensive medication were not taken into account. Multiple
linear regression analysis was used to examine the associations of changes in body weight,
sodium and potassium excretion, alcohol intake and leisure-time physical activity
(times/week) with the changes in BP, controlling for the baseline BP levels. This analysis was
done only in subjects without antihypertensive drug treatment.
   The original target sample size was 800 subjects, which was not reached due to numerous
dropouts before the randomisation among the subjects already recruited. It was estimated that
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this sample size would enable to detect a 3.2 mmHg difference in change of SBP and
a 1.6 mmHg difference in change of DBP between the intervention and usual care groups with
80 % power at the 5 % significance level.
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5 RESULTS
5.1 Trends in community control of hypertension (STUDY 1)
5.1.1 Systolic and diastolic blood pressure levels
   The changes in mean SBP and DBP during 1982 to 1997 stratified by gender, survey year
and study area are shown in Figure 4. During 1982-1987, the mean SBP in men decreased
significantly in Kuopio province and in southwestern Finland, but remained unchanged in
North Karelia. During 1987 to 1997, a downward trend was seen in all three areas. In
Helsinki-Vantaa region, however, the mean SBP of the men did not fall from 1992 to 1997. In
1997, the mean SBP was significantly lower in southwestern Finland compared to the other
areas. During the entire 15-year period, the mean SBP fell 6 mmHg, 7 mmHg and 7 mmHg in
men in North Karelia, Kuopio and southwestern Finland, respectively.
   In women, the mean SBP decreased in Kuopio and in North Karelia during 1982 to 1987,
whereas in southwestern Finland no significant change was observed. A further decrease was
seen in all areas during 1987 to 1997. In 1997, the mean SBP was significantly lower in
southwestern Finland and in Helsinki-Vantaa region compared to the women in Eastern
Finland. During the entire 15-year period, the mean SBP fell 7 mmHg, 10 mmHg and
7 mmHg in women in North Karelia, Kuopio and southwestern Finland, respectively.
   The mean DBP in men remained essentially unchanged in all areas from 1982 to 1987.
There was a significant downward trend in DBP in men during 1987 to 1992, which was
steeper in eastern than in southwestern Finland. During 1982-1992, the mean DBP decreased
by 3, 4 and 1 mmHg in North Karelia, Kuopio and southwestern Finland, respectively. During
next five years, however, the mean values increased slightly but significantly in all areas
except North Karelia.
   There were no significant changes mean DBP among women during 1982-1987. During the
next five years, the mean DBP fell significantly in all areas, but especially in eastern Finland.
During 1992-1997, however, the mean value increased slightly in all areas together. In 1997,
the mean DBP in women was similar in all areas.
69
SBP, men
125
130
135
140
145
1982 1987 1992 1997
Year
mmHg
North
Karelia
Kuopio
Turku-
Loimaa
Helsinki-
Vantaa
Oulu
SBP, women
125
130
135
140
145
1982 1987 1992 1997
Year
mmHg
DBP, men
78
80
82
84
86
88
90
1982 1987 1992 1997
Year
mmHg
North
Karelia
Kuopio
Turku-
Loimaa
Helsinki-
Vantaa
Oulu
DBP, women
78
80
82
84
86
88
90
1982 1987 1992 1997
Year
mmHg
North Karelia-Kuopio-
Turku-Loimaa 1982-1992
All areas except Oulu 1992-1997 All areas 1997
Men Women Men Women Men Women
Systolic BP
Area < 0.001 < 0.001 < 0.001 < 0.001 0.008 < 0.001
Year < 0.001 < 0.001 < 0.001 < 0.001
Area x year 0.003 0.015 0.004 0.590
Diastolic BP
Area 0.001 < 0.001 0.002 0.024 0.001 0.907
Year < 0.001 < 0.001 0.020 0.070
Area x year < 0.001 < 0.001 0.051 0.264
.
    P for analysis of variance, adjusted for age
Figure 4. Systolic and diastolic blood pressure by gender, year and area.
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5.1.2 Prevalence of antihypertensive drug treatment
   The prevalence of antihypertensive drug treatment in men increased steadily in all areas
during the entire study period (Figure 5). In 1997, this proportion was highest, almost 14 %,
in Oulu area. In contrast to men, the proportion of women with antihypertensive drug
treatment decreased slightly in all study areas except Kuopio during 1982-1997. In 1997, the
proportion of female subjects with antihypertensive drug treatment was significantly smaller
in southwestern Finland compared especially to Kuopio.
 P by saturated log-linear model (10-year age group included):
Figure 5. Prevalence of antihypertensive drug treatment (%) by gender, year and area
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Men Women Men Women Men Women
Drug treatment x area < 0.001 < 0.001 0.002 < 0.001 0.306 0.003
Drug treatment x year 0.018 0.316 0.072 0.930
Drug treatment x area x year 0.213 0.592 0.442 0.860
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5.1.3 Prevalence, awareness, treatment and control of hypertension
   The trends in the prevalence, awareness, treatment and control of hypertension according
the two different hypertension criteria are shown in Tables 7 (men) and 8 (women). In men,
the prevalence of hypertension remained at the same level in Eastern Finland, but decreased to
a small extent in southwestern Finland during 1982-1987. During the next five years, vice
versa happened. During 1992-1997, there were no significant changes in the prevalence of
hypertension in any of the areas. In 1997, there was no difference in the prevalence of
hypertension among the areas, irrespective of the hypertension criteria used. In women, the
proportion of hypertensive subjects fell significantly in Kuopio during 1982-1987, but not in
the other areas. During 1987-1997, the proportion of hypertensive women decreased
significantly in all areas. In 1997, this proportion was significantly smaller in southwestern
Finland compared to other study areas.
   In men, awareness of hypertension increased significantly in eastern Finland but not in
southwestern Finland during 1982-1987. During next ten years a continuing upward trend was
seen in all areas, except in Helsinki-Vantaa during 1992-1997 when the upper threshold for
hypertension was used. However, with the lower threshold values, the proportion of aware
hypertensive men increased also in this area. In women, the awareness of hypertension
increased significantly in all areas during 1982-1997. The main part of this increase was
observed during 1992-1997 in all areas but Kuopio. With the higher of the two different
hypertension criteria, at least of 82 % of female hypertensive subjects in each area were aware
of their condition in 1997.
    During 1982-1992, the prevalence of antihypertensive drug treatment among the
hypertensive men increased significantly in all study areas, but especially in eastern Finland.
This increase continued in all areas during 1992-1997. However, even with the higher
threshold for hypertension, at least 55 % of the male hypertensive subjects and 40 % of the
aware hypertensive men in every area were still not receiving antihypertensive drug treatment
in 1997. Also in women, these corresponding proportions increased steadily in all areas
during the entire study period. In 1997, the proportion of hypertensive women with
antihypertensive drug treatment was somewhat higher than in men in all areas.
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Table 7. Prevalence, awareness, treatment and control of hypertension by area and year according to different criteria for hypertension in men.
Study area Hypertension
criteria*
Survey year Prevalence of
hypertension
(%)
Awareness of
hypertension
(%)
On drug-treatment
of those with
hypertension (%)
On drug-
treatment (%) of
those aware of
hypertension
Controlled of
those with
hypertension
(%)
Controlled of
those treated
with  drugs
(%)
North Karelia 1 1982 35 60 30 51 10 35
1987 36 66 33 52 13 39
1992 31 73 41 57 17 42
1997 29 81 44 56 24 54
2 1982 63 44 17 39 2 14
1987 67 47 18 40 2 14
1992 54 54 24 44 4 15
1997 50 62 25 42 7 26
Kuopio 1 1982 37 51 20 41 5 26
1987 37 59 27 47 7 29
1992 30 71 39 55 18 47
1997 30 75 42 56 24 58
2 1982 67 36 11 31 1 12
1987 66 45 15 34 1 9
1992 52 53 23 42 5 21
1997 53 59 24 41 5 21
Turku-Loimaa 1 1982 32 56 27 50 10 36
1987 28 56 29 54 15 54
1992 28 62 32 52 16 49
1997 27 73 40 56 19 47
2 1982 59 38 15 40 2 15
1987 52 38 16 43 3 18
1992 54 43 16 38 2 14
1997 48 55 22 41 3 14
Helsinki- 1 1992 26 71 28 40 13 46
73
Vantaa
1997 29 71 36 52 12 33
2 1992 50 49 15 31 3 20
1997 51 59 21 36 3 15
Oulu 1 1997 31 77 45 60 29 64
2 1997 54 57 25 46 7 29
* 1=SBP>160 mmHg or DBP> 95 mmHg or antihypertensive drug treatment, 2=SBP>140 mmHg or DBP> 90 mmHg or antihypertensive drug treatment
P by saturated log-linear model:
North Karelia-Kuopio-Turku-Loimaa
1982-1992
All areas except Oulu 1992-1997 All areas 1997
Hypertension
criteria 1
Hypertension
criteria 2
Hypertension
criteria 1
Hypertension
criteria 2
Hypertension
criteria 1
Hypertension
criteria 2
Prevalence x area < 0.001 0.200 0.716 0.461 0.237
Prevalence x year < 0.001 0.972 0.139
Prevalence x area x year 0.283 < 0.001 0.420 0.172
Awareness x area < 0.001 0.023 0.002 0.173 0.419
Awareness x year < 0.001 0.008 < 0.001
Awareness x area x year 0.088 0.045 0.403 0.719
Treatment x area < 0.001 0.112 0.011 0.409 0.550
Treatment x year < 0.001 0.028 0.004
Treatment x area x year 0.065 0.026 0.720 0.452
Control x area 0.401 0.004 0.024 < 0.001 0.025
Control x year 0.016 0.047 0.092
Control x area x year 0.032 0.085 0.600 0.623
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Table 8. Prevalence, awareness, treatment and control of hypertension by area and year according to different criteria for hypertension in
women.
Study area Hypertension
criteria*
Survey year Prevalence of
hypertension (%)
Awareness
of
hypertension
(%)
On drug-
treatment of
those with
hypertension (%)
On drug-
treatment of
those aware of
hypertension
(%)
Controlled of
those with
hypertension (%)
Controlled of
those treated
with  drugs
(%)
North Karelia 1 1982 28 77 42 55 14 33
1987 28 74 44 61 20 46
1992 21 81 46 57 25 55
1997 20 88 51 60 28 56
2 1982 50 56 24 43 2 10
1987 47 58 26 47 4 15
1992 39 60 24 40 5 20
1997 37 72 27 39 6 21
Kuopio 1 1982 33 74 39 53 16 41
1987 27 80 43 56 18 43
1992 24 85 49 58 26 53
1997 21 84 61 72 43 71
2 1982 55 57 23 41 2 10
1987 49 58 24 43 2 6
1992 41 66 29 44 6 19
1997 39 69 33 48 10 30
Turku-Loimaa 1 1982 21 69 37 55 17 45
1987 22 70 40 59 20 49
1992 19 70 41 58 25 61
1997 16 82 45 55 30 68
2 1982 40 51 20 40 3 15
1987 38 54 23 45 6 25
1992 35 53 22 41 5 23
1997 31 63 23 37 7 32
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Helsinki-
Vantaa
1 1992 21 79 45 57 27 59
1997 18 85 48 58 31 63
2 1992 35 62 26 43 5 21
1997 31 70 28 41 7 24
Oulu 1 1997 22 85 50 58 34 68
2 1997 37 73 29 40 8 27
1=SBP>160 mmHg or DBP>95 mmHg or antihypertensive drug treatment, 2=SBP>140 mmHg or DBP>90 mmHg or antihypertensive drug treatment
P by saturated log-linear model:
North Karelia-Kuopio-Turku-Loimaa
1982-1992
All areas except Oulu 1992-1997 All areas 1997
Hypertension
criteria 1
Hypertension
criteria 2
Hypertension
criteria 1
Hypertension
criteria 2
Hypertension
criteria 1
Hypertension
criteria 2
Prevalence x area < 0.001 < 0.001 0.004 < 0.001 0.029 0.001
Prevalence x year < 0.001 < 0.001 0.015 0.005
Prevalence x area x year 0.062 0.072 0.864 0.870
Awareness x area < 0.001 < 0.001 0.014 0.004 0.827 0.110
Awareness x year 0.027 0.031 0.013 < 0.001
Awareness x area x year 0.136 0.624 0.371 0.435
Treatment x area 0.147 0.028 0.018 0.013 0.055 0.138
Treatment x year 0.057 0.193 0.022 0.127
Treatment x area x year 0.829 0.617 0.635 0.958
Control x area 0.768 0.221 0.148 0.357 0.049 0.409
Control x year < 0.001 0.002 0.002 0.019
Control x area x year 0.796 0.120 0.226 0.792
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   The hypertensive subjects of the 1997 survey were categorized according to their BP level,
other CVD risk factors and CVD history (Table 9 A-B). Based on this categorization, 46 % of
the men and 57 % of the women with untreated hypertension had mild hypertension with no
or one additional CVD risk factor, i.e. a combination with relatively low CVD risk usually not
requiring institution of antihypertensive drug therapy.
     In hypertensive men, the proportion of subjects with normal BP increased steadily especially
in eastern areas but also in southwestern Finland during the entire study period. In contrast,
this proportion tended to fall in Helsinki-Vantaa region during 1992-1997. Accordingly, the
corresponding proportion in hypertensive women increased in all areas, with the greatest
changes in Kuopio, throughout the study period. In 1997, the proportion of controlled
hypertensive men in Helsinki-Vantaa region was significantly smaller than in other areas
independent of the hypertension criteria used. In women, this proportion was significantly
higher in Kuopio than in other areas in 1997 if using the higher hypertension criteria, but not
if using the lower threshold. The trends in control of hypertension in subjects with
antihypertensive drug treatment were otherwise similar as described above, but in men
a downward trend in control rates were seen since 1987 in southwestern Finland and since
1992 in Helsinki-Vantaa region. In 1997, only 33 % of the treated hypertensive men in
Helsinki had their BP below 160/95 mmHg. In contrast, the corresponding proportion in men
in Oulu was 64 %. With the lower cut-off point for hypertension the control rates were
2-3 times lower depending on the area. Among the inadequately controlled drug-treated
hypertensive patients, 95 % the men and 100 % of the women had undergone a BP
measurement during the previous year (data not shown).
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Table 9 A-B. Distribution (%) of untreated hypertensive subjects  by BP level and associated
cardiovascular risk factors or clinical conditions in the pooled data of the all survey areas of
the FINRISK study in 1997. Table structure modified from (16). The subjects in the
categories within bold frames do not usually require antihypertensive drug treatment based on
their low absolute CVD risk.
A
Men (n=1126)
Grade 1
(mild hypertension)
SBP 140-159 mmHg
or
DBP 90-99 mmHg
Grade 2
(moderate
hypertension)
SBP 160-179 mmHg
or
DBP 100-109 mmHg
Grade 3
(severe
hypertension)
SBP > 180 mmHg
or
DBP > 110 mmHg
No other CVD risk factors1 18 4 1
1 risk factor 28 8 2
2 risk factors 15 6 1
3 or more risk factors or
diabetes
5 2 1
Associated clinical condition2 5 3 1
1 Smoking, serum total cholesterol > 6.5 mmol/l, family history of myocardial infarction under the age
of  60 years, age > 55 years.
2 Myocardial infarction, stroke, heart failure or angina pectoris diagnosed by a physician.
B
Women (n=779)
Grade 1
(mild hypertension)
SBP 140-159 mmHg
or
DBP 90-99 mmHg
Grade 2
(moderate
hypertension)
SBP 160-179 mmHg
or
DBP 100-109 mmHg
Grade 3
(severe
hypertension)
SBP > 180 mmHg
or
DBP > 110 mmHg
No other CVD risk factors1 29 8 1
1 risk factor 28 10 2
2 risk factors 8 3 1
3 or more risk factors or
diabetes
2 0 0
Associated clinical condition2 6 2 0
1 Smoking, serum total cholesterol > 6.5 mmol/l, family history of myocardial infarction under the age
of 60 years.
2 Myocardial infarction, stroke, heart failure or angina pectoris diagnosed by a physician.
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5.2 Trends in cardiovascular risk factors in hypertensive and normotensive populations
(STUDY 2)
5.2.1 Lipid levels and hypercholesterolaemia
   The changes in mean total and HDL cholesterol concentrations are shown in Figure 6. The
mean total cholesterol concentration remained higher in hypertensive groups compared to the
normotensive population during 1982-1997. However, this difference between the
hypertensive and normotensive population decreased throughout the study period. The mean
total cholesterol decreased markedly in both sexes and in every subgroup, but the fall was
most prominent in drug-treated hypertensive patients - 0.86 mmol/l in men and 0.94 mmol/l in
women, respectively.
   The mean HDL cholesterol concentration increased significantly in both sexes and in every
BP group, except in unaware hypertensive men during 1982-1997. In both men and women,
the mean HDL cholesterol remained significantly lower in drug-treated hypertensive patients
compared to the other BP groups during the entire study period. The increase in all BP groups
combined was 0.09 mmol/l in men and 0.17 mmol/l in women, respectively.
   During 1982-1997, the prevalence of hypercholesterolaemia fell significantly in all BP
groups and in both sexes (II, Table 4). The main decline in the prevalence occurred since
1987. In both sexes throughout the study, the proportion of subjects with elevated total
cholesterol remained higher in the hypertensive BP groups compared to the normotensive
population. The prevalence of elevated total to HDL cholesterol ratio decreased significantly
and similarly in every BP group during the study (II, Table 5). However, despite this
favourable development seen also among the drug-treated hypertensive patients, 50 % of men
and 24 % women in this subgroup still had a high ratio in 1997. The corresponding ratios in
1997 in the normotensive men and women were 31 % and 10 %, respectively.
   The awareness of hypercholesterolaemia increased significantly in all BP groups and in
both sexes during 1982-1997 (II, Table 6). During the entire study period, the awareness was
significantly higher in drug-treated hypertensive group compared to other BP groups
(p<0.001). In 1997, 87 % of the drug-treated men and 86 % of the women in the same
subgroup were aware of their high total cholesterol concentration. Among the subjects with
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Figure 6. Mean serum total and HDL cholesterol by gender, year and BP group
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hypercholesterolaemia, cholesterol measurements were done more frequently within the
previous year in drug-treated hypertensive patients compared to the other BP groups during
the entire study period. In 1997, 72 % of the men and 67 % of the women in this subgroup
had their cholesterol measured during the previous year. Also the use lipid-lowering drugs
was most common in this BP group. In 1997, 18 % of the men in this subgroup were using
lipid-lowering agents, whereas the corresponding proportions in the other male BP groups
were 3-5 %. In women, 11 % of the subjects with antihypertensive drug treatment were using
these agents in 1997. The corresponding proportions in other BP groups were 0-1 %. When
the subjects with lipid-lowering drug treatment in 1992 and 1997 were omitted from the
analyses, the observed reductions in mean total cholesterol or increments in HDL-cholesterol
did not change significantly.
5.2.2 Systolic and diastolic blood pressure
   The changes in mean SBP and DBP are shown in Figure 7. During 1982-1997, the mean
SBP decreased significantly in both sexes and in all BP groups. In men, the reduction in SBP
was slightly but significantly greater in hypertensive groups compared to normotensive
subjects. Over the entire 15-year period, the mean SBP decreased by 15 mmHg in women
with antihypertensive drug treatment, which was significantly more than in the other BP
groups.
   In both sexes, the mean DBP decreased significantly only in the group with
antihypertensive drug treatment. Also a small but statistically significant reduction was
observed in normotensive women. The mean DBP in other BP groups remained unchanged.
5.2.3 Smoking
   In men, proportion of current smokers decreased significantly in both normotensive subjects
and in subjects with antihypertensive drug treatment, whereas in other BP groups no change
was detected during 1982-1997 (Figure 8). In normotensive women, the prevalence of
smoking remained unchanged during the study period. In contrast, the proportion of current
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Figure 7. Systolic and diastolic blood pressure by gender, year and BP group.
SBP, women
120
125
130
135
140
145
150
155
160
165
170
1982 1987 1992 1997
Year
mmHg
DBP, men
74
76
78
80
82
84
86
88
90
92
94
96
98
100
102
1982 1987 1992 1997
Year
mmHg
Unaware and
untreated
Aware but
untreated
Treated with
drugs
Normotensive
DBP, women
74
76
78
80
82
84
86
88
90
92
94
96
98
100
102
1982 1987 1992 1997
Year
mmHg
82
Men
0
5
10
15
20
25
30
35
40
45
50
Unaware and untreated
Aware but untreated
Treated with drugs
Normotensive
%
1982
1987
1992
1997
Women
0
5
10
15
20
25
30
35
40
45
50
Unaware and untreated
Aware but untreated
Treated with drugs
Normotensive
%
Men Women
Smoking x BP group < 0.001 0.004
Smoking x study year
Smoking x BP group x study year 0.409 0.421
-1.9 (-10.9, 7.1)
-9.0 (-2.4, -15.7)
-6.3 (-3.2, -9.4)
5.1 (0.2, 9.9)
.
 P by saturated log-linear model (10-year age group included):
Figure 8. The prevalence of smoking and the changes in the prevalence (+ 95 % CI) by
gender, year and BP group.
smokers tended to increase in every female hypertensive subgroup, although the change was
significant only in women with antihypertensive drug treatment. In both sexes, the proportion
of smokers was smallest in subjects with antihypertensive drug treatment and greatest in
normotensive subjects throughout the study period. The prevalence of smoking among the
hypertensive groups with no antihypertensive drug treatment was almost at same level as with
the normotensive population.
   During 1982-1997, the proportion of ex-smokers remained unchanged in every male BP
group (IV, Table 2). In women, this proportion increased significantly in normotensive and in
the aware but untreated group. In men, the proportion of never smokers increased
significantly in the normotensive and in the aware but untreated hypertensive group. Contrary
to men, this proportion decreased significantly in all female BP groups except in unaware
-2.4 (-10.6, 5.8)
4.2 (-5.8, 14.1)
5.1 (-2.5, 12.7) 0.3 (-2.1, 2.6)
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hypertensive subjects. The proportion of current smokers who had tried to quit during the past
year did not change significantly in any of the BP groups in men (IV, Table 3). In women, the
corresponding proportion tended to decrease in all BP groups (interaction between attempt to
quit and survey year, p=0.004). Within the separate subgroups, the decrease was significant
only in the aware but untreated hypertensive subjects. The proportion of male smokers who
reported that they had received advice from their physician during the preceding year to stop
smoking remained unchanged in every BP group during 1982-1997 (IV, Table 4). This
proportion was highest in each survey in drug-treated hypertensive men (interaction between
received advice and BP group, p<0.001). In 1997, 63 % of men in this BP group had received
such advice, which was more than twice that in the normotensive group. In female smokers,
the corresponding proportion tended to increase in every BP group during the study period,
but the increase was significant only in the normotensive group. In 1997, the proportion of
smokers who had received advice to quit was 46-55 % in the hypertensive groups compared
to 29 % in normotensive subjects.
5.2.4 Diabetes
   During 1987-1997, the prevalence of self-reported diabetes increased significantly in men
with antihypertensive drug treatment, but remained unchanged in other BP groups (Table 10).
In women, this proportion did not change significantly in any of the BP groups. In both sexes,
the proportion of diabetics was significantly greater in drug-treated hypertensive patients
compared to the other BP groups. In 1997, 12 % of the men and 7 % of women in this BP
group reported to have diabetes. In 1997, 60 % of the men and 53 % of the women with
antihypertensive drug treatment had their blood sugar concentration determined during the
previous year, whereas the corresponding proportion in every other male or female BP groups
was less than 22 % (data not shown).
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Table 10. The prevalence (%) of self-reported diabetes by gender, year and BP group.
Hypertensive
Untreated and
unaware
Aware but
untreated
Treated with
drugs
Normotensive
Men
1987 1 2 7 2
1992 2 2 6 1
1997 3 2 12 2
Change 2 0 5 0
(95 % CI) (-1, 5) (-3, 3) (0, 10) (-1, 1)
Women
1987 3 1 9 1
1992 2 2 6 1
1997 0 2 7 1
Change -3 1 -2 0
(95 % CI) (-5, 0) (-2, 3) (-7, 2) (0, -1)
P for log-linear analysis (10-year age-group included)
Men Women
Prevalence x BP group < 0.001
Prevalence x study year 0.026
Prevalence x BP group x study year 0.794 0.318
5.3 Trends in lifestyle factors affecting blood pressure in hypertensive and
normotensive populations (STUDY 2)
5.3.1 Body mass index, obesity and waist circumference
The mean BMI in men increased significantly in all BP groups during the 15-year period
(Figure 9). This increase in BMI was significantly greater in the hypertensive groups
compared to normotensive subjects. In women, the mean BMI increased significantly in all
BP groups except in the unaware but untreated hypertensive subjects. During 1982-1997, the
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Figure 9. Mean body mass index by gender, year and BP group.
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Figure 10. Prevalence of obesity (BMI  > 30 kg/m2) and the changes in prevalence (+95 CI)
by gender, year and BP group.
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 mean BMI remained significantly lower in the normotensive subjects compared to the
hypertensive groups in both sexes. In both men and women, the mean BMI was highest in the
drug-treated hypertensive group in every survey.
   The prevalence of obesity increased significantly in every male BP group during 1982-1997
(Figure 10). In women, this increase was seen only in normotensive and unaware
hypertensive subjects. In 1997, 47 % of the drug-treated hypertensive men and 49 % of the
women in this same BP group were obese. The corresponding proportions in the
normotensive men and women were 12 % and 14 %, respectively.
   The changes in the mean waist circumference in different BP groups followed the same
pattern as the changes in BMI: The mean waist circumference increased significantly in every
BP group of both sexes during 1987-1997 (Table 11). This increase tended to be greater in
hypertensive groups compared to normotensive subjects. In every survey, the waist
circumference was highest in the group with antihypertensive drug treatment
5.3.2 Alcohol consumption
   The mean alcohol consumption increased significantly in all BP groups of both sexes during
1982-1997 (Table 12). In men, this increase was significantly greater in hypertensive groups
compared to the normotensive subjects. In women, the increase was greater in the two
untreated hypertensive groups compared to the drug-treated hypertensive or to the
normotensive subjects. In 1997, the mean alcohol consumption was highest in the two
untreated hypertensive groups in both sexes.
5.3.2 Leisure-time physical activity
During 1982-1997, the proportion of subjects with leisure-time physical activity at usually
recommended level (at least three times per week for at least 30 minute per session) increased
significantly in all BP groups and in both sexes, except in unaware hypertensive women
(Table 13). This increase was of the same magnitude in every male BP group. In women, the
increase was most prominent the drug-treated hypertensive patients and in normotensive
subjects. In 1997, these two BP groups were the two most physically active groups in both
sexes.
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Table 11. Mean waist circumference (cm + SD) by gender, study year and BP group.
Hypertensive
Untreated and
unaware
Aware but
untreated
Treated with
drugs
Normotensive
Men
1987 94.7 + 10.3 98.0 + 11.2 100.9 + 11.2 90.0 + 9.6
1992 97.1 + 11.5 100.8 + 11.1 103.0 + 12.2 92.0 + 10.1
1997 99.7 + 12.5 101.1 + 10.9 103.6 + 12.6 91.9 + 10.1
Change 5.0 3.1 2.7 1.9
(95 % CI) (2.9, 7.1) (1.0, 5.1) (0.7, 4.7) (1.2, 2.6)
Women
1987 83.7 + 11.0 84.8 + 11.4 88.8 + 12.7 77.5 + 10.2
1992 86.9 + 12.8 86.9 + 12.8 90.4 + 12.0 79.0 + 10.8
1997 89.8 + 13.2 87.6 + 15.2 92.1 + 13.4 79.4 + 11.1
Change 6.1 2.8 3.3 1.9
(95 % CI) (2.9, 9.4) (0.1, 5.6) (1.2, 5.5) (1.3, 2.6)
P for analysis of variance, adjusted for age:
Men Women
Study year < 0.001 < 0.001
BP group < 0.001 < 0.001
Study year x BP group 0.087 0.067
.
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Table 12. Mean alcohol consumption (g/week + SD) by gender, study year and BP group.
Hypertensive
Untreated and
unaware
Aware but
untreated
Treated with
drugs
Normotensive
Men
1982 65 + 102 81 + 149 42 + 75 63 + 104
1987 84 + 112 83 + 125 66 + 104 69 + 114
1992 102 + 133 117 + 152 94 + 112 87 + 118
1997 137 + 159 136 + 147 107 + 158 91 + 128
Change 72 55 65 28
(95 % CI) (51, 94) (29, 82) (47, 84) (21, 36)
Women
1982 12 + 52 10 + 29 7 + 26 16 + 36
1987 19 + 29 23 + 41 16 + 30 24 + 39
1992 50 + 72 29 + 56 29 + 64 30 + 47
1997 42 + 65 40 + 57 28 + 49 33 +45
Change 30 30 21 17
(95 % CI) (14, 47) (23, 38) (16, 27) (15, 20)
P for analysis of variance, adjusted for age:
Men Women
Study year < 0.001 < 0.001
BP group < 0.001 < 0.001
Study year x BP group < 0.001 < 0.001
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Table 13. The proportion of subjects (%) with leisure-time physical activity at least three
times per week and at least to 30 minutes by gender, year and BP group.
Hypertensive
Untreated and
unaware
Aware but
untreated
Treated with
drugs
Normotensive
Men
1982 20 17 20 23
1987 21 21 24 26
1992 28 24 36 33
1997 33 30 36 36
Change 13 13 16 13
(95 % CI) (5, 22) (5, 20) (9, 24) (11, 16)
Women
1982 20 17 18 18
1987 21 29 23 20
1992 26 30 32 32
1997 28 31 37 39
Change 8 14 19 21
(95 % CI) (-3, 20) (5, 23) (11, 26) (18, 23)
P for log-linear analysis (10-year age-group included)
Men Women
Physical activity x BP group < 0.001
 Physical activity x study year < 0.001
 Physical activity x BP group x study year 0.957 0.043
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5.4 Non-pharmacological treatment of hypertension in primary health care (STUDY 3)
5.4.1 Baseline characteristics and adherence to treatment
   The mean age of the 715 participants was 54.3 years. Of them, 52 % were on
antihypertensive drug treatment in the beginning of the trial (V, Table 1). There were no
statistically significant differences between the groups in any of the baseline variables
analysed. Attendance rates at the one-year and two-year study visits were satisfactory
(V, Figure 1). The attendance rate to both group meetings organised for the intervention group
after six and 18 months of intervention was 50 %. At baseline, the dropouts were significantly
younger (50 vs. 55 years) and heavier (83.1 kg vs. 80.1 kg) compared with the completers of
the study (data not shown). Also alcohol use (73 g/week vs. 42 g/week) and proportion of
smokers (13 % vs. 7 %) were significantly higher among the dropouts.
5.4.2 Changes in blood pressure and related lifestyle factors
   Without taking into account the effect of antihypertensive drug treatment, the reduction in
DBP during the first study year was significantly greater in the intervention group compared
to the usual care group (V, Table 2). The reductions in SBP at the one-year and two-year
follow-ups and in DBP from baseline to two years tended to be greater in the intervention
group, although they did not reach the level of statistical significance. In the subgroup with no
antihypertensive drug treatment, the reductions in both SBP and DBP were significantly
greater in the intervention group compared with the usual care group during both the first and
the second year of follow-up (Figure 11). In subjects with antihypertensive drug treatment at
baseline, the BP reductions were of the same magnitude in both groups. Among the subjects
with antihypertensive drug treatment, the self-reported frequency of BP measurements during
the previous year decreased significantly more in the intervention group during the first year
(Table 14). Otherwise the number of BP measurements did not differ significantly between
the groups during any phase of the study.
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Figure 11. Changes in SBP and DBP from baseline to 1- and 2-year visits stratified by
antihypertensive drug treatment status.   
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Table 14. Changes in number of self-reported BP measurements (95 % CI in parentheses)
done during previous year.
No antihypertensive drug
treatment
Antihypertensive drug
treatment
All
Intervention Usual care Intervention Usual care Intervention Usual
care
Baseline 4.6 5.4 8.6 8.9 6.7 7.3
Change 0-1 year 1.1 0.1 -1.7 0.7 -0.3 0.4
Change 0-2 years 1.2 -0.1 -2.5 -1.4 -0.7 -0.8
Net change 0-1 year 1.0 (-0.3, 2.3) -2.3 (-4.3, -0.3) -0.7 (-1.9, 0.5)
Net change 0-2 years 1.3 (-0.2, 2.8) -1.0 (-2.7, 0.6) 0.1 (-1.0, 1.3)
   The net reductions (intervention vs. usual care) in weight at one and two years of follow-up
were significant. Eight percent of the initially overweight participants (BMI > 25 kg/m2)
assigned to intervention had achieved normal weight at the end of the trial, which was
significantly more than that in the usual care group (V, Table 4). Also the waist and hip
circumferences decreased significantly more in the intervention group than in usual care
throughout the study. The changes in 24-hour urinary sodium and potassium excretion were
small, with no significant differences between the groups. Self-reported alcohol consumption
fell significantly more during the first study year in the intervention group, but this difference
disappeared during the second year. Compared to the usual care group, a significantly larger
proportion of the participants in the intervention group had increased their physical activity to
the target level by both one-year and two-year visits.
   The net reduction in weight between the randomised groups was significantly greater in the
group with no antihypertensive drug treatment during the first year compared to the group
with antihypertensive drug treatment (-1.5 kg vs. -0.8 kg, p for the interaction term 0.021), but
such a difference was not detected in the analysis from baseline to two years. Similarly, the
net reductions in alcohol consumption from baseline to one-year and two-year visits were
significantly greater in this group compared to the group with antihypertensive drug treatment
(from baseline to 1-year visit -17 g/week vs. 1 g/week, p for the interaction term 0.025; from
baseline to two-year visit -9 g/week vs. 5g /week, p for the interaction term 0.029).
93
The response for the intervention in terms of lifestyle changes did not differ significantly
between the sexes or according to the baseline age. In a multiple linear regression analysis
including only the subjects without antihypertensive drug treatment, a positive relation with
two-year SBP and DBP change was found for weight change (SBP, p=0.003; DBP, p<0.001),
but not for the changes in other lifestyle variables. In a separate analysis, adjusting for both
BP and weight at baseline, the estimated effect of the 1kg weight lost at two years was
a reduction of 0.55 mmHg in SBP and 0.50 mmHg in DBP.
5.4.3  Changes in other cardiovascular risk factors
   After two years of intervention, the net changes in total (-0.10 mmol/l) and in
LDL cholesterol (-0.15 mmol/l) were significant in favour of the intervention group
(V,Table 2). Also in persons without lipid-lowering drug treatment during the study the
reductions in total cholesterol  (-0.11 mmol/l; 95 % confidence interval –0.20 to -0.02) and in
LDL cholesterol (-0.13 mmol/l; 95 % confidence interval –0.22 to -0.03) were larger in the
intervention group than in the control group (data not shown). Smoking was rare already at
baseline, and no significant changes in that habit were observed during the study. The serum
insulin concentration decreased more among the persons assigned to intervention, but the net
change was not statistically significant.
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6 DISCUSSION
6.1 Methodological issues
6.1.1 Study populations
   In Studies 1 and 2, the subjects of each population survey originated from independent
random samples drawn from the population register of the study areas. In addition, the
samples were stratified according to sex and 10-year age group. Therefore, the samples can be
considered to be representative of the target population, justifying the comparisons between
the areas in cross-sectional setting and between the surveys in time trend analysis. The
participation rates of the surveys declined over time especially in men, but were still quite
satisfactory in the last survey in 1997. In 1992, a special telephone survey was organised for
the non-participants (385). In this survey, 50 % of the non-participants could be contacted.
Among the non-participants the smoking prevalence was 53 %, which was significantly
greater than that of participants. Otherwise, there were no significant differences between the
participants and non-participants of the survey. Hence, a minor part of the decrease in
smoking prevalence in men during 1982-1997 could be related to decline in participation
rates.
   In the primary health care trial (Study 3) the participants were recruited mostly by the
newspaper announcements. As usual in volunteer-based intervention studies, the participants
were probably more likely to accept the recommended lifestyle advice than the hypertensive
population at large. On the other hand, many volunteers in lifestyle intervention studies are
more likely to have previously changed their lifestyle, which could reduce the power of
intervention. The participants of the study 3 had lower levels of total cholesterol, BMI and
alcohol consumption compared to the aware hypertensive subjects in the FINRISK study in
1997 (see Study 2). In addition, the prevalence of smoking was lower and the proportion of
subjects with recommended levels of leisure-time physical activity was greater than in the
subjects in Study 2. Among the subjects without antihypertensive drug treatment, the levels of
SBP and DBP were lower compared to the FINRISK population. Surprisingly, the BP levels
were similar in both studies among the drug-treated hypertensive subjects. In addition, the
participants of the primary health care trial came from a geographical area with a long history
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of cardiovascular prevention activities, and thus many of them already had a good knowledge
of the lifestyle factors affecting BP (11).
6.1.2 Risk factor measurements
   The accuracy of BP measurements in epidemiological surveys is of paramount importance.
The technique employed must be capable of detecting small changes and differences in BP
levels within and between populations that are trivial at the individual level, but very
important from the public health point of view (386).  The main sources of systematic error in
BP measurement in these population surveys are differences in equipment and differences
between the observers in the technique used. In Studies 1 and 2, the BP measurements were
taken in each survey by a small number of well-trained study nurses, who were circulated
between the survey areas. The nurses spent approximately same length of time in each study
area and the BP values and last digit frequencies of each measurer were monitored during the
surveys. A standard mercury sphygmomanometer with the same cuff size was used in each
survey. In the analysis of the BP measurement data of WHO MONICA baseline surveys, the
quality of BP measurements in the three FINMONICA areas was considered high (387).
   The diagnosis of hypertension in the WHO MONICA surveys, as usual in epidemiological
studies, was based on casual BP, i.e. the BP was measured on only one occasion. According
to a Canadian study, this can lead to the overestimation of the prevalence of hypertension and
to the underestimation in rates for awareness, treatment and control of high BP (388).
In addition to the number of BP measurements used, also the chosen cut-off point for elevated
BP strongly affects the epidemiological estimates of hypertension (367), and also the
observed trends in them as seen in the present study. Hence, the upper cut-off point for
hypertension used in this study (160/95 mmHg) could probably correspond quite well to the
recommended clinical diagnosis of hypertension with follow-up measurements and a lower
cut-off point for hypertension (140/90 mmHg). On the other hand, as shown in many large-
scale studies, also the subjects with casual BP >140/90 mmHg are at increased risk for
cardiovascular events related to hypertension (276). Therefore, this lower threshold for
elevated BP is justified and is also nowadays more widely used than before in studies of the
community control of hypertension in different parts of the world.
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   In Study 3, all the BP measurements were performed by the same study nurse except in one
health care centre, where another trained study nurse did the baseline measurements. There
was only a 0.2/0.5 mmHg difference in mean SBP/DBP measured by these two nurses when
ten volunteer subjects had their BP measured twice with a double-headed stethoscope method.
The accuracy of BP measurements by the principal study nurse was assessed annually with
a double-headed stethoscope. All the BP measurements were done with a standard mercury
sphygmomanometer using the same technique as in the population surveys (Studies 1 and 2).
   The reliability of self-reported smoking tested against biomarker measurements related to
smoking has been reported as satisfactory in most study types (389). In the present study,
serum cotinine levels were measured in the risk factor survey conducted in 1992. In this
survey, the self-reporting of smoking was in good agreement with these biomarker
measurements (390). On the other hand, it can be speculated that the hypertensive population
could be more likely to deny their smoking habit, since they have been advised to quit
smoking more often than normotensive subjects. However, there are no data to confirm this
suggestion, nor should this aspect affect the trends observed. The smoking habits were
assessed with exactly the same standard set of questions in both Studies 2 and 3.
   The estimation of the prevalence of diabetes (Study 2) was based on self-reporting, which
could have led in theory to misclassification of subjects. When the prevalence of diabetes
based on 2-hour glucose tolerance tests was determined in the same survey population aged
45-64 years in 1987, the proportion of diabetic patients was 5.7 % in men and 4.6 % in
women, respectively (391). The corresponding proportions of self-reported diabetes (dietary
or drug treatment) in this same population in 1987 were 4.0 % in men and 3.1 % in women
(data not shown). Hence, the self-reporting could have led to a slight underestimation of the
prevalence of diabetes. Similarly, the self-reporting of alcohol consumption and leisure-time
physical activity (Studies 2 and 3) could have had led to underestimation and overestimation
of these variables, respectively. However, there are no better or more feasible methods to
assess these variables in epidemiological studies. Again, the observed trends and changes in
these variables should not be affected by missestimation, because same set of questions were
used in each survey.
   All the laboratory analyses in Studies 2 and 3 were performed in the same central
laboratory. In both studies, the commercial kits for cholesterol determinations were changed
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during the study, and this was also taken account in the HDL cholesterol analyses of Study 2.
The change of methods did not affect the corresponding analyses in Study 3.
   24-hour urinary collection can  be a very demanding procedure for some study subjects.
Usually the 24-hour urinary creatinine is determined to ascertain the completeness of the
collection. In the primary health care intervention trial, the urinary creatinine was determined
only at 1- and 2-year visits due to a misunderstanding. However, there were no statistically
significant differences in the mean 24-hour urinary creatinine values between the randomised
groups at either of these visits or between the visits within the groups (data not shown). In
addition, the completeness of collection was checked and registered at each annual visit by
a trained study nurse.
6.2  Results
6.2.1 Trends in community control of hypertension (STUDY 1)
   The results of Study 1 showed that the SBP levels and the prevalence of hypertension
decreased significantly in all three FINMONICA areas during 1982-1992 in both sexes. In
contrast, the levels of DBP in both men and women decreased only in eastern Finland. During
the next five years in men, the mean SBP decreased further in all areas except in Helsinki-
Vantaa. The mean DBP showed a slight upward trend, however,  and the prevalence of
hypertension remained unchanged in all areas. In women, the mean SBP and the prevalence
of hypertension decreased significantly in all areas, whereas the mean DBP did not change.
Significant progress took place in awareness, treatment and control of hypertension
throughout the 15-year study period in both men and women of all areas. In 1997, there were
statistically significant differences in rates for control between the study areas in both sexes,
but the rates for awareness and treatment were pretty much the same. The previous
differences between eastern and southwestern Finland in the prevalence of hypertension had
disappeared in men and had also diminished in women.
   It has been estimated that antihypertensive drug therapy explained no more than 10-15 % of
the observed decreases in mortality from stroke and ischaemic heart disease in Finland during
1972-1992 (392). Approximately 10 % of the population were using antihypertensive drugs
during 1982-1997. In these subjects, as demonstrated in Study 2, the change in mean SBP in
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men during the same time period was of the same magnitude as in the rest of the male
population. On the contrary, in women the decrease in SBP was greatest in the group with
antihypertensive drug treatment. It can therefore be proposed that less than 10 % of the
observed decrease in SBP of the entire population could be attributed to the more efficient use
of antihypertensive drugs. Hence, the observed trends in the BP level of the population are
largely explained by changes in lifestyle.
   The dietary intake of sodium and saturated fat has decreased markedly in Finland during
1982-1997, contributing to the observed decline in BP (393, 394). In addition, as
demonstrated in Study 2, the proportion of subjects with recommended level of physical
activity has increased. Unfortunately, the mean BMI and alcohol consumption of the
population has increased continuously, counterbalancing the situation in lifestyle factors
affecting BP. It could be speculated that one of the possible reasons for the continuing
downward trend in mean SBP could be the steady decrease in mean serum cholesterol levels.
The development of atherosclerosis and stiffening of the arteries, which can lead to elevation
of SBP, may thus be delayed (395). It has also been proposed that a fall in serum LDL
cholesterol could improve the endothelial vasodilatation capacity and thereby decreases BP
(284).
   The main part of the detected improvement in different aspects of hypertension care in
Finland during the study period can be attributed to the reorganizing of the hypertension care
system and to intensified health education in the community (396). Compared to the recent
population surveys in some other European countries using the same criteria for hypertension
(see Table 3), the prevalence of hypertension in Finnish men in 1997 was approximately one
third higher than in these countries. In contrast, the rates for prevalence in women were of the
same magnitude across the populations. The awareness of hypertension in Finland in 1997
was at least at the same level as in these countries. However, the rates for treatment were
somewhat lower in Finland compared to other countries. Correspondingly, the proportion of
drug-treated subjects with normal BP was smaller in Finnish men, but not in women.
Interestingly, the rates for awareness, treatment and control of hypertension were significantly
higher in the third National Health and Nutrition Examination Survey (NHANES III) in
U.S.A. compared to any of the European populations (366). The reasons for these differences
among populations are not clear, but they could at least partly be explained by the differences
among the national hypertension guidelines, especially in recommendations for the initiation
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of antihypertensive drug treatment. At least previously, guidelines in the U.S.A. have used
a lower threshold for treatment than the guidelines published in other countries (352).
   In Finland the biggest problem in hypertension care has shifted from detection to the
adequate treatment of high blood pressure. Among the Finnish drug-treated hypertensive
patients of this study, 33-64 % of the men and 56-71 % of the women had their BP
inadequately controlled in 1997. Practically all of them had had their BP measured during the
previous year. Thus, this finding suggests that one of the possible reasons for poor BP control
among this patient-group could be the lack of aggressiveness in treating the patients. The
other well-known reason for not achieving the goal pressure is poor patient compliance.
According to some studies, only 50-60 % of the patients adhere well to the prescribed
antihypertensive medication (397-399). In addition, the hypertension guidelines published in
the early 90's have been criticized due to inconsistency, complexity and inability to clarify the
absolute benefits of treatment, thus increasing the burden for physicians in achieving
normotension or cardiovascular risk reduction in their hypertensive patients (400). At least
partly for this reason, in the most recent hypertension guidelines the treatment decisions are
based on the estimated absolute cardiovascular risk of the patient (15-17, 35). This approach,
using a risk chart as tool for better management for hypertension, has already demonstrated to
carry a larger potential for hypertension control than the treatment policy based on crude BP
values (401).
   The threshold for the initiation of antihypertensive drug treatment in low-risk patients
(subjects with mild hypertension, i.e. 140-159/90-99 mmHg, and no other CVD risk factors)
or medium-risk patients (subjects with mild hypertension and 1-2 other CVD risk factors or
subjects with moderate hypertension, i.e.160-179/100-109 mmHg, and 0-2 other CVD risk
factors) is somewhat different among the current hypertension guidelines. In the WHO
hypertension guidelines, antihypertensive drug therapy should be initiated in the  low-risk
group within 6-12 months if SBP/DBP remains at the level of >150/95 mmHg, and in the
medium-risk group within 3-6 months at the BP level of 140/90 mmHg, respectively (16). In
contrast, the 1997 Joint National Committee (JNCVI) hypertension guidelines recommend the
initiation of antihypertensive drug treatment for all subjects with ascertained moderate
hypertension immediately, and for all subjects with sustained mild hypertension within 6-12
months (15). The just recently published Finnish guidelines are in accordance with the US
guidelines in treatment of subjects with moderate hypertension (35). However, they are more
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conservative than the US guidelines in respect of the treatment schedule in patients with mild
hypertension. According to the Finnish guidelines, the antihypertensive drug therapy should
be added to lifestyle modification in this patient-group, only if the absolute 10-year risk for
CVD events exceeds 20 %. If this recommendation is applied to the FINRISK population, in
most men and in almost all women with mild hypertension and 0-1 additional CVD risk factor
antihypertensive drug therapy is not necessarily warranted.
   In the future, the criteria used for evaluation of hypertension care in and between the
populations could also be based on estimated absolute cardiovascular risk instead of BP
values alone, at least when calculating the rates for antihypertensive drug treatment among the
hypertensive subjects. This kind of approach was recently used in a Swedish population-based
study, which applied the latest WHO hypertension guidelines to a WHO MONICA sample of
6000 subjects in Northern Sweden (402). In this study, the untreated hypertensive subjects
were stratified into groups of different levels of absolute cardiovascular risk, i.e. to the groups
justified or not justified to receive antihypertensive drug treatment according to the current
evidence. The distribution of untreated hypertensive subjects across the low-, medium-, high-
and very high-risk groups in the present study (Table 9A-B) was very much similar to this
Swedish study. In both studies, the vast majority of these subjects belonged to the low- or
medium-risk group.
6.2.2 Trends in cardiovascular risk factors and in lifestyle factors affecting blood
pressure (STUDY 2)
6.2.2.1  Lipid levels and hypercholesterolaemia
   The mean total cholesterol levels of both the normotensive and hypertensive population of
both sexes fell continuously during the entire 15-year study period. A significant increase in
mean HDL cholesterol was observed in every BP subgroup except in men unaware of their
hypertension. Similarly, the prevalence of hypercholesterolaemia decreased significantly
across the BP groups. The awareness of hypercholesterolaemia increased markedly, and thus
in 1997 more than 80 % of the drug-treated hypertensive subjects were aware of their high
cholesterol level.
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   The main reasons for the observed favourable trends in total and HDL cholesterol trends are
the dietary changes observed in the Finnish diet since 1972. During 1972-1992, the changes in
fat intake included the decrease in total fat content of the diet from 38 % of total energy intake
to 34 %, the decrease in saturated fat intake from 21 % to 16 % and the increase in the
polyunsaturated fat intake from 3 % to 5% of total energy intake (393). Simultaneously, the
majority of the population changed from boiled to filtered coffee, which may also have
contributed to the decrease in mean total cholesterol of the population. One of the factors
behind these dietary changes include launching of the North Karelia Project and other
population-based cardiovascular disease prevention programmes since the 1970's, which have
increased the public awareness of the health risks connected to elevated cholesterol.
In addition, at least a part of the observed trends are due to changes in the legislation
concerning dietary fats and their manufacture. In 1987, the Finnish Cardiac Society and
Internists' Association published their recommendations on screening for
hypercholesterolaemia in the general population. According to these recommendations, every
adult aged 20 years or more should have his or her cholesterol level determined every 5 years.
This is one of the obvious reasons for rapid rise in awareness of hypercholesterolaemia that
has taken place especially since 1987.
   The mean decline in total cholesterol among men was of the same magnitude in all BP
groups between 1982 and 1992. During the next five years, the steepest fall was seen in the
group with antihypertensive drug treatment (0.6 mmol/L). It could be proposed that a change
of such a magnitude could not have been achieved without the reported increase in the use of
lipid-lowering medication during the same time period (from 9 % to 18 %). However, when
the subjects using these agents were left out from the analyses, the observed fall in mean total
cholesterol remained equally large. This finding suggests that the main reason for the change
was related to dietary changes, induced possibly by the dietary counselling given by health
personnel. In women, the total cholesterol fell more in drug-treated hypertensive patients
compared to the normotensive subjects already during 1982-1992. The decrease was similar
in all BP groups during 1992-1997 except for the unaware hypertensive subjects, where
a small sample size during the two last surveys could have affected the trends observed.
   Despite the proven benefits of a multifactorial treatment approach in hypertensive subjects
(403), the prevalence of lipid-lowering drug therapy in Finnish hypertensive subjects in 1997
was still unexpectedly low. Similar results have been reported also in other studies (404).
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It has been reported that one of the reasons for such an apparent undertreatment of
hypercholesterolaemia in this high-risk patient group is the inconsistency between the official
guidelines for treatment for hypercholesterolaemia and an inappropriate dissemination of
these guidelines to practising physicians (405, 406).
   The results of the present study demonstrating significantly lower levels of HDL cholesterol
in drug-treated hypertensive subjects compared to the other three BP groups are in accord
with the findings of other population-based studies (18, 19, 370). The consistency of the
findings suggests that the antihypertensive drug treatment can cause reductions in HDL
cholesterol that are important at the public health level. During the study period, beta-blockers
and diuretics, which are both known to have the ability to lower HDL cholesterol (407), still
remained as the most frequently prescribed antihypertensive drugs in Finland (408).
The increasing trend in prescribing metabolically more neutral beta-blockers, low-dose
diuretics, calcium channel blockers and ACE-inhibitors during the study period in Finland did
not affect this difference between the BP groups in mean HDL cholesterol. The low level of
HDL cholesterol among the drug-treated hypertensive patients was also the most important
contributing factor for the high prevalence of the elevated ratio of total to HDL cholesterol
detected in both sexes of this BP group.
6.2.2.2  Smoking
   According to the results of the present study the prevalence of smoking in normotensive
men as well as in drug-treated hypertensive men decreased significantly in Finland during
1982-1997. An increasing trend in the proportion of smokers was observed in all female BP
groups, but the change was significant only in the drug-treated hypertensive group.
The proportion of current smokers who had been advised to quit by their doctor during the
last year increased slightly but significantly in normotensive women, but not in any other
female or male BP group.
   In Finland, the prevalence of smoking in both men and women is nowadays among the
lowest in Europe. Since the early 1960's, the proportion of smokers has decreased by one half
in men. Among women, smoking was fairly rare until the 1970's, but since then a significant
increase has occurred. During 1972-1982, the decrease in smoking prevalence in men was
mainly explained by the increased smoking cessation, but since 1982 the decrease in the
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numbers starting to smoke has been the main reason for the continuing trend (409).
The contributing factors for the observed decrease in smoking include several preventive
activities targeted against smoking and the passing of the first tobacco control legislation in
1977, which was updated in 1995. In women, the observed increase in smoking prevalence
among the middle-aged women was mainly due to an augmented rate of smoking initiation
among young women in the 1960's and the 1970's, suggesting a cohort effect. Since then the
initiation rate among the youngest age groups has remained rather stable. In contrast to men,
smoking cessation has increased steadily among women also since 1982, though not sufficient
to prevent the moderate upward trend in female smoking.
   According to many prospective studies, continued smoking is one of the main determinants
for excess mortality among treated hypertensive subjects (12, 292). Therefore, activities
targeting smoking cessation are of major importance especially in this patient-group.  In the
present study, the proportion of ex-smokers was significantly higher in treated hypertensive
patients throughout the study period compared with other BP groups. However, this
proportion remained rather stable also in this BP group, indicating that the decrease in
smoking prevalence was mainly due to decreased smoking initiation. In fact, that the
proportion of smokers remained unchanged and was of the same magnitude in the two
untreated hypertensive groups as in the normotensive subjects in 1997 was alarming.  In
women, the observed increase in smoking in the drug-treated hypertensive group was mainly
caused by an increased initiation rate.
   Patient education for smoking cessation is one of the cornerstones in the treatment of
hypertension as recommended by the most recent Finnish as well as international
hypertension guidelines (15-17, 35). In this study, the proportion of current smokers being
recently advised by their physician to quit was significantly greater in the drug-treated
hypertensive men in every survey compared with three other male BP groups. In women, the
situation was somewhat similar until 1997, when the proportion of smokers who had been
recently encouraged to quit increased in the two untreated hypertensive groups to the same
level as in the drug-treated group. Despite this observed difference in health counselling
between the BP groups, there were no differences between the groups in self-reported
attempts to quit smoking among the current smokers. Paradoxically, at the same time as the
proportion of normotensive smoking women being advised to quit during 1982-1997
increased, the rate of quitting attempts tended to decrease. In both genders, the small number
104
of ex-smokers who had managed to quit smoking during the preceding year did not allow to
make any comparison between them and current smokers in terms of provision of
anti-smoking advice.
   Individual behavioural counselling alone or combined with nicotine-replacement therapy or
antidepressants are strategies used in clinical trials that have proven efficacy in smoking
cessation (410-412). In the future, to increase the efficacy of advice offered by physicians
against smoking, these strategies should be used more routinely as a part of multifactorial
cardiovascular risk approach in the treatment of hypertensive patients. One barrier for
achieving this goal is the somewhat limited knowledge among physicians on how to
implement these strategies in practice. One of the key elements to overcome this barrier could
be the creation of national smoking cessation guidelines such as those already developed for
the treatment of hypertension and dissemination of these guidelines to all practicing
physicians. More routine involvement of nurses in anti-smoking counselling in co-operation
with physicians could also represent one solution to this problem (413).
6.2.2.3  Diabetes, obesity, alcohol use and physical activity
   The results of the present study showed that mean BMI increased significantly in every BP
group during the 15-year study period except in aware but untreated hypertensive women.
The proportion of obese women increased especially in aware hypertensive men and in
unaware hypertensive women. The prevalence of self-reported diabetes increased
significantly in drug-treated hypertensive men, but not in any other male or female BP groups.
   Obesity results from the imbalance between energy intake and energy expenditure. In
Finland, the mean total energy intake decreased significantly during 1972-1992 (393).
Unfortunately, according to another Finnish study, the energy expenditure during work and
during moving to and from work decreased even more (414). The reported simultaneous
increase in leisure-time physical activity was not enough to counterbalance the situation. It
was concluded in this same report that in the future the promotion of daily, moderate-intensity
activities could be the most feasible method to increase the energy increase and thereby
decrease the burden of obesity at the population level.
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   Obesity, especially abdominal obesity, is a strong predictor of type 2 diabetes (415). On the
other hand, as recently shown in a Finnish landmark study, type 2 diabetes can be prevented
in subjects with impaired glucose tolerance by weight reduction and other changes in lifestyle
similar to the ones to be used in treatment of high BP (416). In the present study, the
increasing trends in both obesity and in waist circumference in men with antihypertensive
drug treatment may have contributed to the observed increase in self-reported diabetes during
the study. However, such an increase in the prevalence of diabetes was not seen in any other
of the male or female BP group despite the similar trends in BMI and waist circumference
across the BP groups. Other explanations are therefore possible. Drug-treated hypertensive
subjects are usually under regular follow-up and have their blood sugar determined more
often than the subjects in the other BP groups, as reported also in this study. The diagnosis of
symptom-free diabetes is thus more evident in this BP group compared to the other groups.
Diuretics and especially beta-blockers have the ability to increase insulin resistance (417,
418). The wide use of these drug classes during the study period may also at least partially
explain the higher prevalence of diabetes in both men and women with antihypertensive drug
treatment (408).
   In Finland the hypertensive subjects who are aware of their elevated BP are usually under
regular follow-up, which is carried mainly by primary health care nurses and doctors. This
follow-up includes monitoring of the efficacy of drug treatment and health counselling about
adverse lifestyles, including obesity, excess intake of salt and alcohol, physical inactivity and
smoking. According to the results of this study, the mean BMI and weekly alcohol
consumption increased especially in this patient-group. In addition, only one third of these
subjects in both sexes reported as having practised leisure-time physical activity at the
recommended level in 1997.  Therefore, as also shown in some previous studies (419), there
is an urgent need for more effective measures in lifestyle counselling of hypertensive patients
in  Finnish primary health care.
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6.2.3  Non-pharmacological treatment of hypertension in primary health care
(STUDY 3)
   The Study 3 is probably the first large-scale controlled trial reporting the effects of lifestyle
intervention on BP and other cardiovascular risk factors in hypertensive persons in primary
care setting. The small reductions in BP and lipid levels achieved in this study are in accord
with the changes detected in trials of multiple risk factor intervention or dietary intervention
with people at high risk but not necessarily hypertensive (259, 264, 420). In contrast, the BP
reduction observed in the subjects without antihypertensive drug treatment was smaller
compared to some clinical trials of non-pharmacological treatment of hypertension (69, 96).
However, this BP reduction can be considered as important from the public health point of
view. A small number of current smokers among the participants made it at least partly
difficult to achieve any significant reduction in proportion of smokers during the study.
   The achieved weight reduction in our study was of the same magnitude than in some trials
with much more intensive intervention (21). The intervention program could not bring about
any significant reductions in salt intake. Despite the fact that in 95 % of the participants the
weekly alcohol consumption was already at the recommended level at baseline, a small but
significant reduction in alcohol intake occurred in the intervention group during the first year.
Self-reported leisure-time physical activity increased significantly more in the intervention
group throughout the study.
   According to the separate analysis of the dietary data of this study, the proportion of fat,
especially saturated fats, from total energy intake (E%) decreased significantly more in the
intervention group compared to usual care (the net reductions at two years; total fat intake
-2.7 %  E% and saturated fat intake -1.7 E%) (384). Also the total energy intake tended to
decrease more in the intervention group, although not reaching the level of statistical
significance. In addition to the increase in physical activity, these changes in diet may have
contributed to the observed differences in changes of body weight, lipid levels and BP
between the randomised groups. The dietary data were in accordance with the results of the
24-hour urinary sodium excretion showing no significant changes in sodium intake. These
results repeat the findings of the many other studies that have demonstrated the difficulties in
achieving the recommended level of salt intake in free-living subjects (101, 421). It has been
suggested that the main reason for this difficulty in salt restriction seen in all western
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countries is the still relatively high concentration of salt in processed foods (422). Therefore,
in the future, one of the cornerstones in the reduction of salt intake in the whole population is
the close collaboration with the food industry to increase the production of low-salt food
items.
   The differences in BP reduction observed between the groups could not be explained by
accustomisation with BP measurement, because there were no differences in self-reported
frequency of BP measurements between the groups during the study. One explanation for the
greater fall in blood pressure among the participants who continued antihypertensive drug
treatment compared with the participants without antihypertensive drugs could be a more
regular use of antihypertensive drugs during the trial than before.
   In addition to the factors related with the volunteering of the participants, also the
"contamination" of the control group due to the fact their follow-up visits were done by the
same nurses as with the intervention group might have reduced the difference in the lifestyle
changes between the groups. Also the fact that they were under systematic observation in an
interesting study likely influenced them. It is also worth noticing that most of the study
subjects were under regular follow-up provided by the health centres already before the study.
Therefore, the favourable changes observed in the lifestyle factors of the intervention group
were based mostly on the change in the way how lifestyle counselling was provided, not on
the initiation of it. Thus, our observed effects of the intervention, as usual in this kind of
study, are likely to be conservative.
   The principal aim of  Study 3 was to find out the extent to which lifestyle intervention will
work in the usual primary health care setting. From this point of view, the results of the study
were quite satisfactory, considering the limited requirement for the use of health care
resources. The potential of the intervention shown in this study can certainly be much
improved by further development and systematic dissemination, especially concerning newly
detected hypertensive persons. Non-pharmacological treatment of hypertension has been
advocated for a long time, but so far only limited evidence and experience has been available
as to its effective implementation within the primary care. The task is not easy due to the
limited time and resources that the public health service can allocate for such preventive
services. However, the present study demonstrates that also this approach works.
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7    SUMMARY AND CONCLUSIONS
   This doctoral thesis consisted of three separate studies that assessed different aspects of
community control of hypertension in Finland. In the first study, the trends in BP levels and in
the prevalence, awareness and control of hypertension were assessed in cross-sectional
surveys of the representative samples of the population aged 25-64 years in eastern and
southwestern Finland during 1982-1997 and in Helsinki-Vantaa area during 1992-1997.
In 1997, also the Oulu region was included in the study areas. The second study examined the
trends in cardiovascular risk factors and in lifestyle factors affecting BP in aware and unaware
hypertensive subjects of the southwestern and eastern Finland during 1982-1997 and
compared the observed trends with those seen in the normotensive population. In the third
study, the efficacy of a lifestyle counselling programme targeting BP reduction in
hypertensive subjects was assessed in a two-year randomised controlled trial organised in ten
primary health  centres in eastern Finland.
   The results of the three studies can be summarized as follows:
1. The mean SBP levels and the prevalence of hypertension decreased significantly in
both sexes in eastern and southwestern Finland during 1982-1992. The mean DBP
decreased only in eastern Finland. During next five years in men, the mean SBP
decreased in all areas except in the Helsinki-Vantaa area, and the mean DBP and
the prevalence of hypertension remained stable in all areas. In women the mean
SBP and the prevalence of hypertension decreased further in all study areas, but
also in women the mean DBP remained unchanged. The rates for awareness,
treatment and control of hypertension increased significantly in both sexes and in
all areas throughout the study period, except in men in Helsinki-Vantaa during
1992-1997.
2. The mean total cholesterol and prevalence of hypercholesterolaemia decreased
significantly in both hypertensive and normotensive subjects of both sexes during
1982-1997. The mean HDL cholesterol increased markedly in all BP groups except
in men unaware of their hypertension, but the mean value remained at significantly
lower level in drug-treated hypertensive patients compared to subjects with no
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antihypertensive drug treatment. The prevalence of smoking decreased significantly
in normotensive men and in men with antihypertensive drug treatment, whereas
an upward trend in smoking was seen in drug-treated hypertensive women. The
prevalence of self-reported diabetes increased significantly in men with
antihypertensive drug treatment, but not in the rest of the population. The mean
BMI and waist circumference increased significantly in the whole population, but
especially in hypertensive subjects. Alcohol consumption increased more in the
hypertensive subjects of the both sexes compared to the normotensive population.
Self-reported leisure-time physical activity increased in all BP groups except in
unaware hypertensive women.
3. The two-year lifestyle intervention programme conducted in primary health care
produced significantly greater reductions in BP levels of the subjects with no
antihypertensive drug treatment assigned to intervention compared to subjects
receiving usual care. This difference in BP reduction was mainly attributed to the
decrease in mean body weight and to the increase in leisure-time physical activity,
which were significantly greater in the intervention group during the study.
The differences in BP reduction between the randomised groups were not
statistically significant among the subjects with antihypertensive drug treatment.
   It can be concluded that the control of hypertension has improved markedly in Finland
during 1982-1997. Despite this favourable development, intensified efforts for both "the
individual approach"- and "the population approach"-strategies are needed in the future to
improve the situation further. Firstly, the unfavourable trends in BMI and in alcohol
consumption of the whole population should be reversed. In addition, the observed increase in
leisure-time physical activity and the decrease in salt intake should be maintained to shift the
distribution of the population BP further to the left. Secondly, the health behaviours of newly
diagnosed hypertensive subjects should be carefully monitored and modified in primary
health care in a more systematic and efficient way than presently. Lastly, effective
antihypertensive drug treatment should be initiated in subjects with moderate or high
cardiovascular risk early enough if lifestyle modification does not achieve satisfactory results.
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